<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">68542</article-id><article-id pub-id-type="doi">10.7554/eLife.68542</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-231100"><name><surname>Gludovacz</surname><given-names>Elisabeth</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1837-2422</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-235445"><name><surname>Schuetzenberger</surname><given-names>Kornelia</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-233770"><name><surname>Resch</surname><given-names>Marlene</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-233771"><name><surname>Tillmann</surname><given-names>Katharina</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233772"><name><surname>Petroczi</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-176018"><name><surname>Schosserer</surname><given-names>Markus</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2025-0739</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233773"><name><surname>Vondra</surname><given-names>Sigrid</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233774"><name><surname>Vakal</surname><given-names>Serhii</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233775"><name><surname>Klanert</surname><given-names>Gerald</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-89008"><name><surname>Pollheimer</surname><given-names>Jürgen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8440-5221</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233776"><name><surname>Salminen</surname><given-names>Tiina A</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233777"><name><surname>Jilma</surname><given-names>Bernd</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-233778"><name><surname>Borth</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-233779"><name><surname>Boehm</surname><given-names>Thomas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8294-0797</contrib-id><email>thomas.boehm@meduniwien.ac.at</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Biotechnology, University of Natural Resources and Life Sciences</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff2"><label>2</label><institution>Department of Clinical Pharmacology, Medical University of Vienna</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff3"><label>3</label><institution>Center for Medical Physics and Biomedical Engineering, Medical University of Vienna</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff4"><label>4</label><institution>Center for Biomedical Research, Medical University of Vienna</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff5"><label>5</label><institution>Department of Obstetrics and Gynecology, Medical University of Vienna</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff6"><label>6</label><institution>Strutural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University</institution><addr-line><named-content content-type="city">Turku</named-content></addr-line><country>Finland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mangoni</surname><given-names>Arduino A</given-names></name><role>Reviewing Editor</role><aff><institution>Flinders Medical Centre</institution><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Diamond</surname><given-names>Betty</given-names></name><role>Senior Editor</role><aff><institution>The Feinstein Institute for Medical Research</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>03</day><month>09</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e68542</elocation-id><history><date date-type="received" iso-8601-date="2021-03-18"><day>18</day><month>03</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-09-01"><day>01</day><month>09</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Gludovacz et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Gludovacz et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-68542-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-68542-figures-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Excessive plasma histamine concentrations cause symptoms in mast cell activation syndrome, mastocytosis, or anaphylaxis. Anti-histamines are often insufficiently efficacious. Human diamine oxidase (hDAO) can rapidly degrade histamine and therefore represents a promising new treatment strategy for conditions with pathological histamine concentrations.</p></sec><sec id="abs2"><title>Methods:</title><p>Positively charged amino acids of the heparin-binding motif of hDAO were replaced with polar serine or threonine residues. Binding to heparin and heparan sulfate, cellular internalization and clearance in rodents were examined.</p></sec><sec id="abs3"><title>Results:</title><p>Recombinant hDAO is rapidly cleared from the circulation in rats and mice. After mutation of the heparin-binding motif, binding to heparin and heparan sulfate was strongly reduced. The double mutant rhDAO-R568S/R571T showed minimal cellular uptake. The short α-distribution half-life of the wildtype protein was eliminated, and the clearance was significantly reduced in rodents.</p></sec><sec id="abs4"><title>Conclusions:</title><p>The successful decrease in plasma clearance of rhDAO by mutations of the heparin-binding motif with unchanged histamine-degrading activity represents the first step towards the development of rhDAO as a first-in-class biopharmaceutical to effectively treat diseases characterized by excessive histamine concentrations in plasma and tissues.</p></sec><sec id="abs5"><title>Funding:</title><p>Austrian Science Fund (FWF) Hertha Firnberg program grant T1135 (EG); Sigrid Juselius Foundation, Medicinska Understödsförening Liv och Hälsa rft (TAS and SeV).</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>diamine oxidase</kwd><kwd>histamine</kwd><kwd>heparin</kwd><kwd>heparan sulfate proteoglycan</kwd><kwd>clearance</kwd><kwd>half-life</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Rat</kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>T1135</award-id><principal-award-recipient><name><surname>Gludovacz</surname><given-names>Elisabeth</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006306</institution-id><institution>Sigrid Juséliuksen Säätiö</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Vakal</surname><given-names>Serhii</given-names></name><name><surname>Salminen</surname><given-names>Tiina A</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010116</institution-id><institution>Medicinska Understödsföreningen Liv och Hälsa</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Vakal</surname><given-names>Serhii</given-names></name><name><surname>Salminen</surname><given-names>Tiina A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Because heparin-binding motif mutations of human diamine oxidase (hDAO) block cellular uptake and strongly decrease clearance in vivo, modified recombinant hDAO might be a good candidate for the treatment of symptoms induced by excessive endogenous histamine release.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s6" sec-type="intro"><title>Introduction</title><p>The biogenic amine histamine (2-[4-imidazolyl]ethylamine) is stored by basophils and mast cells (MCs) and is rapidly released after stimulation from intracellular storage vesicles. Following activation of the histamine receptors 1 and 2, histamine acts mainly on vascular endothelial, bronchial, and smooth muscle cells and causes symptoms affecting the cardiovascular system, the skin, and the gastrointestinal and respiratory tracts (<xref ref-type="bibr" rid="bib23">Jutel et al., 2009</xref>; <xref ref-type="bibr" rid="bib46">Valent et al., 2011</xref>). It induces nitric oxide synthesis, which causes vasodilation, vascular hyperpermeability, edema formation, and consequently hypotension (<xref ref-type="bibr" rid="bib1">Ashina et al., 2015</xref>; <xref ref-type="bibr" rid="bib10">Claesson-Welsh, 2015</xref>; <xref ref-type="bibr" rid="bib34">Pober and Sessa, 2015</xref>; <xref ref-type="bibr" rid="bib47">Valent et al., 2019</xref>). The development of hypotension strongly correlates with histamine concentrations (<xref ref-type="bibr" rid="bib24">Kaliner et al., 1982</xref>). Multiple potentially life-threatening conditions such as mast cell activation syndrome (MCAS) or anaphylaxis are accompanied by elevated histamine levels (<xref ref-type="bibr" rid="bib46">Valent et al., 2011</xref>). In severe anaphylaxis, mean histamine concentrations of 140 ng/mL have been measured (<xref ref-type="bibr" rid="bib49">van der Linden et al., 1992</xref>).</p><p>The copper-containing amine oxidase human diamine oxidase (hDAO; E.C. 1.4.3.6) is a homodimer encoded by the <italic>AOC1</italic> gene (<xref ref-type="bibr" rid="bib3">Barbry et al., 1990</xref>; <xref ref-type="bibr" rid="bib9">Chassande et al., 1994</xref>), which is highly expressed in the intestine (<xref ref-type="bibr" rid="bib51">Wollin et al., 1998</xref>), the kidneys (<xref ref-type="bibr" rid="bib41">Schwelberger et al., 1998</xref>), and extravillous trophoblasts (<xref ref-type="bibr" rid="bib50">Velicky et al., 2018</xref>). In pregnancy serum, hDAO at a mean concentration of 125 ng/mL rapidly degraded 100 ng/mL histamine with a half-life of 3.4 min (<xref ref-type="bibr" rid="bib6">Boehm et al., 2019</xref>). In the 1930s, porcine diamine oxidase was already used to treat histamine-related pathologies with limited success (<xref ref-type="bibr" rid="bib29">Laymon and Cumming, 1939</xref>; <xref ref-type="bibr" rid="bib31">Miller and Piness, 1940</xref>). After intravenous infusion of recombinant hDAO (rhDAO) in rats and mice, the half-life was less than 5 min (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). The rapid clearance was not caused by binding of the N-glycans to the asialoglycoprotein- or the mannose-receptor. Diamine oxidase did not only bind to but was also internalized by various epithelial and endothelial cell lines. Internalization was inhibited by high molecular weight heparin (HMWH), and glycosaminoglycan- and heparan sulfate (HS)-deficient CHO cell lines were incapable of rhDAO uptake. Diamine oxidase is produced by intestinal and proximal tubular kidney epithelial cells and binds to the basolateral membranes in the lamina propria after secretion into the interstitial compartment and in vitro also to endothelial cells (<xref ref-type="bibr" rid="bib42">Schwelberger et al., 1999</xref>; <xref ref-type="bibr" rid="bib51">Wollin et al., 1998</xref>). It is released from its binding sites by heparin infusion, resulting in an increase in plasma activity (<xref ref-type="bibr" rid="bib4">Biebl et al., 2002</xref>; <xref ref-type="bibr" rid="bib14">D’Agostino et al., 1989</xref>; <xref ref-type="bibr" rid="bib17">Gäng et al., 1975</xref>; <xref ref-type="bibr" rid="bib21">Hansson and Thysell, 1973</xref>; <xref ref-type="bibr" rid="bib28">Klocker et al., 2004</xref>; <xref ref-type="bibr" rid="bib27">Klocker et al., 2000</xref>). Robinson-White et al. described the binding of rat placental DAO to rat and guinea pig microvascular endothelial cells and its displacement by heparin, indicating that DAO binds to cell surface heparan sulfate proteoglycans (HSPG) (<xref ref-type="bibr" rid="bib37">Robinson-White et al., 1985</xref>). During anaphylaxis, secretion of heparin from MCs likely results in DAO release from HSPG located in the extracellular matrix or on the surface of gastrointestinal epithelial cells (<xref ref-type="bibr" rid="bib6">Boehm et al., 2019</xref>). Cell surface HSPG probably mediate cellular binding and/or uptake of rhDAO.</p><p><xref ref-type="bibr" rid="bib32">Novotny et al., 1994</xref> proposed that the amino acids 568–575 or RFKRKLPK constitute a heparin-binding motif (HBM) (<xref ref-type="bibr" rid="bib32">Novotny et al., 1994</xref>). These amino acid stretches form a ring-like structure including the motifs of both monomers on the surface of DAO (<xref ref-type="bibr" rid="bib30">McGrath et al., 2009</xref>). No negatively charged amino acids are close to this positively charged ring structure (<xref ref-type="bibr" rid="bib30">McGrath et al., 2009</xref>). The putative heparin-binding site of hDAO possesses the size, shape, and electrostatic properties suitable for heparin and HS binding (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). However, it has never been demonstrated, neither in vitro nor in vivo, that the RFKRKLPK sequence mediates heparin and HS binding.</p><p>The short half-life of rhDAO in rats and mice is highly unfavorable for the development of rhDAO as a new treatment option for diseases with rapid and excessive histamine release from MCs or basophils. We herein demonstrate for the first time that rhDAO rapidly degrades pathophysiologically relevant histamine concentrations. Using appropriate mutations in the RFKRKLPK sequence, we prove the heparin binding function of this ring structure motif and its involvement in the ultra-rapid plasma clearance of rhDAO. The HBM mutants show a strongly decreased binding to heparin and HS, minimal cellular internalization, and a strong reduction of the in vivo clearance in rodents with unchanged catalytic activity. This study provides promising data for the development of rhDAO as a first-in-class biopharmaceutical for the treatment of conditions with elevated systemic histamine concentrations.</p></sec><sec id="s7" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="top"><bold>Reagent type (species) or resource</bold></td><td align="left" valign="top"><bold>Designation</bold></td><td align="left" valign="top"><bold>Source or reference</bold></td><td align="left" valign="top"><bold>Identifiers</bold></td><td align="left" valign="top"><bold>Additional information</bold></td></tr><tr><td align="left" valign="top">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="top"><italic>AOC1</italic></td><td align="left" valign="top">GenBank</td><td align="left" valign="top">HGNC: 80</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pRMCE-hDAO (plasmid)</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib18">Gludovacz et al., 2016</xref></td><td align="left" valign="top"/><td align="left" valign="top">hDAO-WT expression vector</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pRMCE-hDAO-R568S (plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">R568S mutant of hDAO</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pRMCE-hDAO-R571T (plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">R571T mutant of hDAO</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pRMCE-hDAO-K575T (plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">K575T mutant of hDAO</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pRMCE-hDAO-R568S/R571T (plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">R568S/R571T mutant of hDAO</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pRMCE-hDAO-R568S/K575T (plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">R568S/K575T mutant of hDAO</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pRMCE-hDAO-R571T/K575T (plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">R571T/K575T mutant of hDAO</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pRMCE-hDAO- K570G/R571Q/K572T (plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">K570G/R571Q/K572T mutant of hDAO</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pRMCE-hFcDAO (plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">Fusion of human IgG Fc and hDAO</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pRMCE-hFcDAO-R568S/R571T (plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">Fusion of human IgG Fc and R568S/R571T mutant of hDAO</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">R568S-FP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">ttcaaaaggaagctgccc</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">R568S-RP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">gctgaaggccgcctggc</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">R571T-FP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">acgaagctgcccaagtacc</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">R571T-RP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">tttgaagcggaaggc</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">K575T-FP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">acgtacctgctctttaccagcc</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">K575T-RP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">gggcagcttccttttga</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">R568S/R571T-FP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">aaaacgaagctgcccaagtacctg</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">R568S/R571T-RP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">gaagctgaaggccgcctgg</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">R571T/K575T-FP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">gcccacgtacctgctctttaccagccc</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">R571T/K575T-RP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">agcttcgttttgaagcggaaggc</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">K570G/R571Q/K572T-FP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">cagacgctgcccaagtacctgct</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="top">K570G/R571Q/K572T-RP</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PCR primers</td><td align="left" valign="top">tccgaagcggaaggccg</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">rhDAO-WT</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib18">Gludovacz et al., 2016</xref></td><td align="left" valign="top"/><td align="left" valign="top">Recombinant human diamine oxidase, wildtype</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">rhDAO-R568S</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">R568S mutant of rhDAO-WT</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">rhDAO-K575T</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">K575T mutant of rhDAO-WT</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">rhDAO-R568S/R571T</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">R568S/R571T mutant of rhDAO-WT</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">rhDAO-R568S/K575T</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">R568S/K575T mutant of rhDAO-WT</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">rhDAO- K570G/R571Q/K572T</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">K570G/R571Q/K572T mutant of rhDAO-WT</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">rhFcDAO</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">Human IgG Fc-rhDAO fusion protein</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">rhFcDAO-R568S/R571T</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">Human IgG Fc-rhDAO-R568S/R571T fusion protein</td></tr><tr><td align="left" valign="top">Cell line (<italic>Cricetulus griseus</italic>)</td><td align="left" valign="top">CHO-K1_rhDAO-WT</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib18">Gludovacz et al., 2016</xref></td><td align="left" valign="top"/><td align="left" valign="top">CHO-K1 stably expressing rhDAO-WT</td></tr><tr><td align="left" valign="top">Cell line (<italic>C. griseus</italic>)</td><td align="left" valign="top">CHO-K1_rhDAO-R568S</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">CHO-K1 stably expressing rhDAO-R568S</td></tr><tr><td align="left" valign="top">Cell line (<italic>C. griseus</italic>)</td><td align="left" valign="top">CHO-K1_rhDAO-K575T</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">CHO-K1 stably expressing rhDAO-K575T</td></tr><tr><td align="left" valign="top">Cell line (<italic>C. griseus</italic>)</td><td align="left" valign="top">CHO-K1_rhDAO-R568S/R571T</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">CHO-K1 stably expressing rhDAO-R568S/R571T</td></tr><tr><td align="left" valign="top">Cell line (<italic>C. griseus</italic>)</td><td align="left" valign="top">CHO-K1_rhDAO-R567S/K575T</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">CHO-K1 stably expressing rhDAO- R567S/K575T</td></tr><tr><td align="left" valign="top">Cell line (<italic>C. griseus</italic>)</td><td align="left" valign="top">CHO-K1_rhDAO- K570G/R571Q/K572T</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">CHO-K1 stably expressing rhDAO- K570G/R571Q/K572T</td></tr><tr><td align="left" valign="top">Cell line (<italic>C. griseus</italic>)</td><td align="left" valign="top">CHO-K1_rhFcDAO</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">CHO-K1 stably expressing rhFcDAO</td></tr><tr><td align="left" valign="top">Cell line (<italic>C. griseus</italic>)</td><td align="left" valign="top">CHO-K1_ rhFcDAO-R568S/R571T</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">CHO-K1 stably expressing rhFcDAO-R568S/R571T</td></tr><tr><td align="left" valign="top">Cell line (<italic>C. griseus</italic>)</td><td align="left" valign="top">ExpiCHO-S</td><td align="left" valign="top">Thermo Fisher Scientific</td><td align="left" valign="top">Cat#: A29133RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_5J31">CVCL_5J31</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>C. griseus</italic>)</td><td align="left" valign="top">CHO-K1</td><td align="left" valign="top">ATCC</td><td align="left" valign="top">Cat#: CCL-61RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0214">CVCL_0214</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">SK-Hep1</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat#: 91091816RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0525">CVCL_0525</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">HUVEC67</td><td align="left" valign="top">Evercyte</td><td align="left" valign="top">Cat#: CPT-006-0067</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">HUVEC/TERT2</td><td align="left" valign="top">Evercyte</td><td align="left" valign="top">Cat#: CHT-006-0008RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_9Q53">CVCL_9Q53</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">HDMVEC/TERT164-B</td><td align="left" valign="top">Evercyte</td><td align="left" valign="top">Cat#: CHT-013-0164-B</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">HDF76</td><td align="left" valign="top">Evercyte</td><td align="left" valign="top">Cat#: CPT-008-0076</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">PODO/TERT256</td><td align="left" valign="top">Evercyte</td><td align="left" valign="top">Cat#: CHT-033-0256RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_JL76">CVCL_JL76</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">LHCN-M2</td><td align="left" valign="top">Evercyte</td><td align="left" valign="top">Cat#: CkHT-040-231-2RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_8890">CVCL_8890</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">HepG2</td><td align="left" valign="top">ATCC</td><td align="left" valign="top">Cat#: HB-8065RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0027">CVCL_0027</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">HeLa</td><td align="left" valign="top">Ellmeier Lab – Medical University of Vienna</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">EVT</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib50">Velicky et al., 2018</xref></td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-ABP1 (rabbit polyclonal)</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat#: SAB1410491-100UG</td><td align="left" valign="top">IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Alexa Fluor 488 anti-rabbit (H + L) (donkey polyclonal)</td><td align="left" valign="top">Jackson Research</td><td align="left" valign="top">Cat#: 711-545-152RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2313584">AB_2313584</ext-link></td><td align="left" valign="top">IF (1:500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">IgG serum fraction (rabbit polyclonal)</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib5">Boehm et al., 2017</xref></td><td align="left" valign="top"/><td align="left" valign="top">WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">β-actin mAB (AC-15) (mouse monoclonal)</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: AM4302RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2536382">AB_2536382</ext-link></td><td align="left" valign="top">WB (1:5000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">IRDye 800CW anti-rabbit IgG (H + L) (goat polyclonal)</td><td align="left" valign="top">Li-Cor</td><td align="left" valign="top">Cat#: 926-32211RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_621843">AB_621843</ext-link></td><td align="left" valign="top">WB (1:5000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">IRDye 680RD anti-mouse IgG (H + L) (goat polyclonal)</td><td align="left" valign="top">Li-Cor</td><td align="left" valign="top">Cat#: 925-68070RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2651128">AB_2651128</ext-link></td><td align="left" valign="top">WB (1:5000)</td></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Histamine</td><td align="left" valign="top">Sigma-Aldrich</td><td align="char" char="." valign="top">Cat#: 53300</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Heparin</td><td align="left" valign="top">Gilvasan</td><td align="left" valign="top">1000 IU/mL</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Heparin (sodium salt from intestinal mucosa)</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat#: H3149</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Diminazene aceturate</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat#: D7770</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">Cisbio HTRF histamine 500 test kit</td><td align="left" valign="top">Biomedica</td><td align="left" valign="top">Cat#: 62HTMDPET</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">Immunotech histamine ELISA</td><td align="left" valign="top">Beckman Coulter</td><td align="left" valign="top">Cat#: IM2562</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">ExpiCHO Expression System Kit</td><td align="left" valign="top">Thermo Fisher Scientific</td><td align="left" valign="top">Cat#: A29133</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">R (version 3.6.3)</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib35">R Development Core Team, 2020</xref></td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">Kaluza Flow Cytometry Analysis Software (version 2.1)</td><td align="left" valign="top">Beckman Coulter</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">ImageJ/Fiji</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib39">Schneider et al., 2012</xref></td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">Pymol (version 2.0)</td><td align="left" valign="top">The PyMOL Molecular Graphics System, version 2.0 Schrödinger, LLC</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">Chimera</td><td align="left" valign="top">UCSF</td><td align="left" valign="top"/><td align="left" valign="top">AmberTools GUI incorporated</td></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">BIOVIA Discovery Studio 2019</td><td align="left" valign="top">Dassault Systemes</td><td align="left" valign="top"/><td align="left" valign="top">Modeller 9.2 GUI incorporated</td></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">FoldX 4.0</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib43">Schymkowitz et al., 2005</xref></td><td align="left" valign="top"/><td align="char" char="." valign="top"/></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">DAPI stain</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat#: D1306</td><td align="left" valign="top">(80 ng/mL)</td></tr></tbody></table></table-wrap><sec id="s2-1"><title>Examination of histamine degradation</title><p>Degradation of 100 ng/mL histamine (Sigma-Aldrich, St. Louis, MO, 53300) by 6 nM (1 µg/mL) rhDAO variants was measured in duplicate in phosphate buffered saline (PBS) with 1% human serum albumin (HSA; Albunorm; Octapharma, Vienna, Austria) or in EDTA plasma from a healthy volunteer, with or without 600 nM HMWH added (heparin, 1000 IU/mL equivalent to 2 mg/mL, Gilvasan, Vienna, Austria), using a Cisbio HTRF histamine 500 test kit (Biomedica, Vienna, Austria).</p><p>Plasma of seven mastocytosis patients and three healthy volunteers was spiked with 6 nM rhDAO-WT, 545 nM histamine, and 20 µM of the potent DAO-inhibitor diminazene aceturate (DIMAZ; Sigma-Aldrich, D7770) and histamine concentrations were determined in duplicate with a histamine ELISA (Immunotech IM2562, Beckman Coulter, Brea, CA) as described previously (<xref ref-type="bibr" rid="bib6">Boehm et al., 2019</xref>).</p></sec><sec id="s2-2"><title>Site-directed mutagenesis to create HBM mutants</title><p>To generate rhDAO single and double HBM mutants, the charged amino acids arginine and lysine were replaced with polar threonine and serine by site-directed mutagenesis. Threonine and serine have been used to replace arginine residues in the HBM of fibronectin, resulting in significantly reduced binding affinities, while at the same time retaining the three-dimensional structure (<xref ref-type="bibr" rid="bib8">Busby et al., 1995</xref>; <xref ref-type="bibr" rid="bib25">Kapila et al., 2001</xref>). The triple mutant rhDAO-K570G/R571Q/K572T representing the HBM of guinea pig, dog, rat, mouse, and Chinese hamster DAO was also tested. All mutants were generated from the rhDAO expression plasmid described by <xref ref-type="bibr" rid="bib18">Gludovacz et al., 2016</xref>. The HBM mutants and the respective 5′-phosphorylated primers are summarized in the Key resources table. The cloning procedure is described by <xref ref-type="bibr" rid="bib19">Gludovacz et al., 2018</xref>. Human IgG Fc was fused to the N-termini of rhDAO-WT (rhFcDAO) and rhDAO-R568S/R571T (rhFcDAO-R568S/R571T) using an IgG1 hinge region as a linker. The Fc sequence was synthesized by Eurofins MWG Operon (Ebersberg, Germany), and plasmids were constructed by using the methods described by <xref ref-type="bibr" rid="bib18">Gludovacz et al., 2016</xref>.</p></sec><sec id="s2-3"><title>Expression and purification of the HBM mutants</title><p>Stable CHO-K1 cell lines expressing the different HBM mutants were generated and cultivated as described for the wildtype (<xref ref-type="bibr" rid="bib18">Gludovacz et al., 2016</xref>). rhDAO-R571T and -R571T/K575T could not be successfully expressed. For batch cultivation, cells were seeded at a viable cell density of 0.2 × 10<sup>6</sup> cells/mL and incubated for 8 days. 10 µM CuSO<sub>4</sub> was added on days 0 and 4. One batch of rhDAO-WT (batch 2) and rhDAO-R568S/R571T (batch 3) was produced with the ExpiCHO expression system (Thermo Fisher Scientific, Waltham, MA) using the standard protocol over 10 days (see ‘ExpiCHO Expression System User Guide,’ MAN0014337). 10 µM CuSO<sub>4</sub> was added on days 0, 2, 4, 6, and 8.</p><p>Culture supernatants were ultra- and diafiltrated using the Labscale TFF System in combination with one to three Pellicon XL 50 Ultrafiltration Cassette-Biomax Polyethersulfone with a 100 kDa molecular mass cutoff (both Merck Millipore, Burlington, MA). The supernatants were concentrated 10- to 50-fold, and the culture media were replaced by 10 mM potassium phosphate buffer, pH 7.4 (Merck Millipore). The samples were loaded onto three 5 mL HiTrap Heparin HP columns connected in series at a flow rate of 2 mL/min using an Äkta Purifier or Start HPLC device (all GE Healthcare, Chicago, IL). Stepwise elution of rhDAO-WT, rhFcDAO, and rhDAO-K575T was performed with 0.25, 0.5, and 1 M KCl. The other HBM mutants were eluted with 0.125, 0.25, and 1 M KCl (Sigma-Aldrich) in 10 mM potassium phosphate buffer, pH 7.4. The eluates containing rhDAO variants were concentrated and desalted using the Labscale TFF System combined with one Pellicon XL 50 Ultrafiltration Cassette and 25 mM Tris-HCl buffer, pH 8.5 (AppliChem, Darmstadt, Germany). This material was loaded onto a 5 mL HiTrap CaptoQ column (GE Healthcare) at a flow rate of 3 mL/min. Stepwise elution was conducted with 0.315 and 1.5 M KCl in 25 mM Tris-HCl buffer, pH 8.5. Buffer exchange of the 0.315 M KCl eluate against 50 mM HEPES with 150 mM KCl, pH 7.5 was performed with the Labscale TFF System and one Pellicon XL 50 Ultrafiltration Cassette. Purified rhDAO was quantified using NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific).</p></sec><sec id="s2-4"><title>Determination of heparin binding using heparin-sepharose</title><p>The storage buffer of purified rhDAO-WT and the HBM mutants was replaced with either 10 mM potassium phosphate, pH 7.4, or 50 mM HEPES, pH 7.4, using Amicon Ultra centrifugal filter units (MWCO 100 kDa, Merck Millipore). They were loaded onto a HiTrap Heparin HP column (1 mL, GE Healthcare) at a flow rate of 0.2 mL/min using an Äkta purifier HPLC device. Elution was performed using a linear gradient of increasing amounts of 1 M KCl in 10 mM potassium phosphate, pH 7.4, or 1 M NaCl in 50 mM HEPES, pH 7.4.</p></sec><sec id="s2-5"><title>Analysis of rhDAO-R568S/R571T binding to HMWH and HS</title><p>Binding of rhDAO-R568S/R571T to HMWH and HS compared to rhDAO-WT was analyzed with ITC using automated MicroCal PEAQ-ITC (Malvern Panalytical, Malvern, UK) and with BLI using Octet RED96e (FortéBio, Fremont, CA) as described previously (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). Sample concentrations and injection modes of all ITC experiments are listed in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. For BLI comparison of binding of the wildtype protein and the R568S/R571T mutant to HS and HMWH, protein concentrations of 471 nM (HS) and 88 nM (HMWH) were used.</p></sec><sec id="s2-6"><title>In vitro cell-based uptake assay</title><sec id="s2-6-1"><title>Cell lines and strains</title><p>The following cell lines and strains were used for the experiments in this study: HepG2, CHO-K1, human dermal fibroblasts (HDF), HeLa, SK-Hep1, primary human extravillous trophoblast cells (EVT), primary human umbilical vein endothelial cells (HUVEC67), immortalized HUVECs (HUVEC/TERT2), immortalized human dermal microvascular endothelial cells (HDMVEC/TERT164-B), immortalized podocytes (PODO/TERT256), and immortalized myoblasts (LHCN-M2). All cell lines were incubated in a humidified atmosphere at 37°C with 5% CO<sub>2</sub> and passaged twice a week.</p><p>Suppliers, catalog numbers, and culture media compositions were recently published (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). The identity of all cell lines has been authenticated. Absence of mycoplasma has been confirmed on a regular basis.</p></sec><sec id="s2-6-2"><title>Flow cytometry</title><p>The cells were seeded into 96-well plates. At confluency, the supernatant was replaced with 50 µL fresh culture medium supplemented with 30 nM Alexa488-labeled rhDAO-WT or rhDAO-R568S/R571T and incubated for 60 min at 37°C. These variants were fluorescently labeled by periodation of vicinal diol groups and subsequent conjugation with an Alexa Fluor 488-hydrazide (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). No DAO added served as a negative control. The cells were washed three times for 5 min with PBS containing 500 µg/mL heparin (sodium salt from intestinal mucosa, Sigma-Aldrich) at room temperature and detached with 50 µL 0.1% trypsin, 0.02% EDTA (Sigma-Aldrich). The reaction was stopped with 50 µL 1× trypsin inhibitor (Sigma-Aldrich, T6414) and addition of 100 µL PBS. 500 cells per cell sample were analyzed on a CytoFLEX S flow cytometer.</p><p>Raw data of fluorescence measurements were analyzed with the help of R version 3.6.3 (<xref ref-type="bibr" rid="bib35">R Development Core Team, 2020</xref>) and RStudio 1.1.463 including the following package: userfriendlyscience version 0.7.2. Data of each tested cell line was loaded into R, log-transformed, and normalized between biological replicates by dividing the data by the median of the respective negative controls. The standard deviations of each cell line were adjusted between biological replicates by dividing the standard deviation of the negative controls of the first biological replicate by the standard deviation of the negative controls of the second biological replicate. This factor was then used to adjust the standard deviation of all samples. The medians of all samples were used for statistical testing. First, a Shapiro–Wilk test was used to test whether the medians were normally distributed. As this was the case for all samples and cell lines, a Bartlett test was used to see whether all samples of a cell line have equal variances. If this was the case, a one-way ANOVA with a Tukey’s HSD test as a posthoc test was used to identify significant differences. If equality of variances could not be assumed, an ANOVA with Welch’s correction and a Games–Howell posthoc test were applied. If a p-value of &lt;0.05 was calculated, significant differences were assumed.</p><p>Background corrected means of the median values ± SEM: median fluorescence intensity values of all samples were calculated with Kaluza Flow Cytometry Analysis Software (Beckman Coulter, version 2.1). After correcting for background fluorescence, the means of the medians ± SEM are presented.</p></sec><sec id="s2-6-3"><title>Fluorescence microscopy</title><p>The cells were seeded into 8-well µ-slides (ibidi, Martinsried, Germany, 80826) 3–4 days prior to the experiments. They were washed once with PBS and then covered with 130 µL of the respective culture medium containing 60–120 nM unlabeled or Alexa488-labeled rhDAO. Incubation was performed at 37°C for 60 min. The cells were washed three times for 5 min with PBS containing 500 µg/mL heparin at room temperature. The cell fixation, permeabilization staining, and imaging procedures were recently published (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>).</p></sec><sec id="s2-6-4"><title>Western blot</title><p>Internalization of rhDAO wildtype and the HBM mutants R568S, R568S/R571T, and R568S/K575T into SK-Hep1 and HUVEC/TERT2 cells was tested as described (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>).</p></sec></sec><sec id="s2-7"><title>Determination of in vivo clearance and DAO antigen and activity</title><p>rhDAO-WT and the different mutants were administered to rats and mice as described (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). DAO antigen concentrations and enzymatic activity were measured in duplicate as published (<xref ref-type="bibr" rid="bib7">Boehm et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Boehm et al., 2017</xref>). The activity curve in the linear range was used to calculate the slope corresponding to the oxidation rate.</p></sec><sec id="s2-8"><title>Ethics statement</title><p>The experimental protocols for the treatment of rats and mice were approved by the local Animal Welfare Committee and the Federal Ministry of Science, Research and Economy (GZ 66.009/0152-WF/V/3b/2014) and conducted in full accordance with the ARRIVE guidelines (<xref ref-type="bibr" rid="bib26">Kilkenny et al., 2010</xref>).</p></sec><sec id="s2-9"><title>Prediction of mutation effects on protein stability and heparin-binding affinity in silico</title><p>The complex of wildtype hDAO and heparin hexasaccharide was constructed as described previously (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). Briefly, the missing side-chain atoms in the DAO dimer were first built with Pymol (The PyMOL Molecular Graphics System, version 2.0, <xref ref-type="bibr" rid="bib40">Schrödinger, LLC, 2021</xref>). Using ClusPro, heparin tetrasaccharide probes were blindly docked into DAO dimer to reveal the heparin-binding site, which was later used for a restrained docking. Heparin hexasaccharide was then manually built by joining two probes in Pymol and subjected to restrained energy minimization using AmberTools GUI incorporated in Chimera (UCSF).</p><p>Three single (R568S, R571T, and K575T), three double (R568S/R571T, R568S/K575T, and R571T/K575T), and one triple (K570G/R571Q/K572T) mutants were built with Modeller 9.2 GUI in BIOVIA Discovery Studio 2019 (Dassault Systemes). Twenty models for each mutant were built without global optimization to avoid driving the conformation too far from the initial one. The model with the lowest probability density function (PDF) total energy and discrete optimized protein energy (DOPE) score was selected as the representative structure. The ‘Side-Chain Refinement’ protocol was then used to optimize the mutated side chains without affecting the overall fold. For each mutant, the electrostatic surface was calculated with the APBS plugin (<xref ref-type="bibr" rid="bib2">Baker et al., 2001</xref>) and visualized in Pymol.</p><p>To predict the effects of the mutations on DAO stability, the FoldX 4.0 (Centre for Genomic Regulation, Spain; <xref ref-type="bibr" rid="bib43">Schymkowitz et al., 2005</xref>) command-line interface and ‘PositionScan’ command were used. Free energy contributions from individual mutations were summed to get total free energy changes.</p><p>Changes in free energy of binding to heparin hexasaccharide were predicted with the ‘Calculate mutation energy (Binding)’ protocol in Discovery Studio 2019 (<xref ref-type="bibr" rid="bib44">Spassov and Yan, 2013</xref>) using the following parameters: pH-dependent electrostatics = true, pH = 7.4, preliminary minimization = false, forcefield = CHARMm Polar H. All other options were used with default values.</p></sec></sec><sec id="s21" sec-type="results"><title>Results</title><sec id="s3-1"><title>rhDAO rapidly degrades endogenous and exogenous histamine</title><p>The lowest published K<sub>m</sub> of rhDAO for histamine is 2.8 µM or 311 ng/mL (<xref ref-type="bibr" rid="bib15">Elmore et al., 2002</xref>). Histamine concentrations inducing clinically relevant hypotension start at approximately 5 ng/mL, which is 62-fold below the K<sub>m</sub>. Is rhDAO able to rapidly degrade histamine using a pathophysiologically relevant histamine concentration range of 5–100 ng/mL? 6 nM (1 µg/mL) rhDAO-WT with and without a 100-fold molar excess of HMWH completely degraded 100 ng/mL histamine in less than 15 min using 1% HSA-PBS or EDTA plasma (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Heparin did not influence DAO activity. Plasma of seven mastocytosis patients and three healthy volunteers with endogenous histamine levels of approximately 5 nM were also spiked with 545 nM exogenous histamine. rhDAO-WT degraded exogenous and endogenous histamine to harmless concentrations below 1 ng/mL. Histamine deamination was completely blocked by addition of the potent DAO inhibitor DIMAZ (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Recombinant human diamine oxidase (rhDAO) efficiently degrades histamine in phosphate buffered saline (PBS) and human plasma samples from mastocytosis patients and healthy volunteers.</title><p>(<bold>A</bold>) 6 nM purified rhDAO-WT with and without 100× high molecular weight heparin (HMWH; 600 nM) were incubated at 37°C for 60 min with 100 ng/mL histamine in 1% human serum albumin-phosphate buffered saline (HSA-PBS) and EDTA plasma of a healthy volunteer. Histamine concentrations were determined in duplicate. Plasma: △; plasma with 100× HMWH: ◇; HSA-PBS: ○; HSA-PBS with 100× HMWH: □. (<bold>B</bold>) Plasma of mastocytosis patients (n = 7) and healthy volunteers (n = 3) was spiked with 6 nM rhDAO-WT, 545 nM histamine, and 20 µM diminazene aceturate (DZ, potent DAO inhibitor) and incubated for 60 min at 37°C. Mean histamine concentrations with standard deviation (SD) as applicable are shown; column Pl (plasma): no histamine and no DAO spiking but with endogenous histamine; column Pl/His/DAO: spiking of exogenous histamine and exogenous DAO; column Pl/His: spiking of exogenous histamine; column Pl/His/DAO/DZ: spiking of exogenous histamine, DAO, and DIMAZ; t-test p-value comparing Pl with Pl/His/DAO data was 0.015 for mastocytosis patients and 0.011 for healthy volunteers; Histamine concentrations in Pl/His and Pl/His/DAO/DZ samples were &gt;500 nM and the SD could not be calculated. Pl: plasma; His: histamine.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68542-fig1-v2.tif"/></fig></sec><sec id="s3-2"><title>The proposed HBM is essential for binding to heparin and heparan sulfate</title><p>We have recently shown in rodents that rhDAO-WT is rapidly cleared from the circulation, precluding its use as a histamine-degrading biopharmaceutical (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). Mutations in the HBM of superoxide dismutase increased the plasma concentration 10-fold (<xref ref-type="bibr" rid="bib38">Sandström et al., 1994</xref>). Based on the superoxide dismutase data and the complete blockade of rhDAO uptake into various cell lines using HMWH (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>), we hypothesized that the proposed HBM of DAO is involved in the rapid clearance of rhDAO in vivo. The tested HBM mutants eluted from the heparin-sepharose at lower salt concentrations than the wildtype protein (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="table" rid="table1">Table 1</xref>). rhDAO-R568S/R571T demonstrated the weakest binding to heparin-sepharose and was therefore further analyzed using isothermal titration calorimetry (ITC) and biolayer interferometry (BLI). rhDAO-WT bound to HMWH with mean (SD) K<sub>D</sub> values of 634 (26) nM in ITC and 1.6 and 69 nM in BLI analyses with likely two DAO molecules binding to one HMWH molecule (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). The mean K<sub>D</sub> values for HS were 4 and 112 nM using BLI. The best curve fit was again generated with a ratio of two molecules DAO binding to one molecule HS (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). rhDAO-R568S/R571T, the rhDAO mutant with the lowest heparin affinity, did not show any binding to HMWH and only minimal binding to HS (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). All raw plots and integrated heat plots of the ITC analyses of the HBM mutant are presented in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Mutuations in the heparin-binding motif of recombinant human diamine oxidase (rhDAO) reduce binding to heparin-sepharose.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="top">rhDAO</th><th align="left" colspan="2" valign="top">NaCl</th><th align="left" colspan="2" valign="top">KCl</th><th align="left" valign="top">Mean (SD)</th></tr><tr><th align="left" valign="top">Concentration (mM)</th><th align="left" valign="top">Reduction (mM)</th><th align="left" valign="top">Concentration (mM)</th><th align="left" valign="top">Reduction (mM)</th><th align="left" valign="top">Reduction (mM)</th></tr></thead><tbody><tr><td align="left" valign="top">WT</td><td align="char" char="." valign="top">372</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">310</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0 (na)</td></tr><tr><td align="left" valign="top">R568S</td><td align="char" char="." valign="top">186</td><td align="char" char="." valign="top">186</td><td align="char" char="." valign="top">172</td><td align="char" char="." valign="top">138</td><td align="char" char="." valign="top">162 (24)</td></tr><tr><td align="left" valign="top">K575T</td><td align="char" char="." valign="top">317</td><td align="char" char="." valign="top">55</td><td align="char" char="." valign="top">233</td><td align="char" char="." valign="top">77</td><td align="char" char="." valign="top">66 (11)</td></tr><tr><td align="left" valign="top">R568S/R571T</td><td align="char" char="." valign="top">175</td><td align="char" char="." valign="top">197</td><td align="char" char="." valign="top">138</td><td align="char" char="." valign="top">172</td><td align="char" char="." valign="top">185 (13)</td></tr><tr><td align="left" valign="top">R568S/K575T</td><td align="char" char="." valign="top">197</td><td align="char" char="." valign="top">175</td><td align="char" char="." valign="top">164</td><td align="char" char="." valign="top">146</td><td align="char" char="." valign="top">161 (15)</td></tr><tr><td align="left" valign="top">K570G/R571Q/K572T<xref ref-type="table-fn" rid="table1fn2">*</xref></td><td align="char" char="." valign="top">219</td><td align="char" char="." valign="top">153</td><td align="left" valign="top">-</td><td align="left" valign="top">-</td><td align="left" valign="top">-</td></tr></tbody></table><table-wrap-foot><fn><p>Purified rhDAO-WT and various HBM mutants were loaded onto a heparin-sepharose column and eluted with linear gradients of 0–1 M NaCl or KCl. The salt concentrations necessary for rhDAO elution and the reduction thereof compared to the wildtype protein are shown. The physiological salt concentration in blood plasma and interstitial fluid is approximately 145 mM.</p></fn><fn id="table1fn2"><label>*</label><p>Corresponds to the HBM in guinea pig, dog, rat, mouse, and Chinese hamster.</p></fn><fn><p>HBM = heparin-binding motif; SD = standard deviation; na = not applicable.</p></fn></table-wrap-foot></table-wrap><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Mutations of the heparin-binding motif of recombinant human diamine oxidase (rhDAO) significantly reduce binding to heparin and heparan sulfate (HS).</title><p>(<bold>A</bold>) Purified rhDAO-WT and various heparin-binding motif (HBM) mutants were loaded onto a heparin-sepharose column and eluted with a linear gradient of increasing NaCl concentration. (<bold>B</bold>) Isothermal titration calorimetry was performed by titrating 25 × 1.5 µL high molecular weight heparin (HMWH) at a concentration of 120 µM into 36.7 µM rhDAO-WT (○) or rhDAO-R568S/R571T (△). The graph represents single experiments for each protein-ligand pair. A summary of all experiments is shown in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. (<bold>C</bold>) Biolayer interferometry. Streptavidin sensors loaded with biotinylated HMWH or HS were incubated for 10 min with 88 nM or 471 nM rhDAO, respectively. Dissociation was measured for 15 min. The graphs represent one of three individual measurements and show the association and dissociation curves after subtraction of the negative control (no DAO added). The data of rhDAO-WT have already been published (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>) but are added for better presentation.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>All raw plots and integrated heat plots of the isothermal titration calorimetry (ITC) analyses of the heparin-binding motif (HBM) mutant are presented in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-68542-fig2-data1-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68542-fig2-v2.tif"/></fig></fig-group></sec><sec id="s3-3"><title>Mutations of the HBM significantly reduce cellular internalization of rhDAO</title><p>rhDAO-WT is rapidly internalized into various cell types (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). To test whether mutations of the HBM not only reduce binding of rhDAO to HMWH and HS, but also inhibit cellular uptake, the single mutant rhDAO-R568S and the two double mutants, rhDAO-R568S/R571T and rhDAO-R568S/K575T, were selected for cellular internalization experiments. SK-Hep1 cells showed a slightly reduced uptake of the single mutant rhDAO-R568S, but a strong decrease for both double mutants (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The other cell lines were only incubated with rhDAO-WT and the double mutant rhDAO-R568S/R571T. The wildtype protein showed intracellular granular staining. The fluorescence signal using the mutant was comparable to the negative controls with no DAO added (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Recombinant human diamine oxidase (rhDAO) heparin-binding motif (HBM) double mutants show significantly reduced uptake into various cell lines.</title><p>(<bold>A</bold>) SK-Hep1, primary human umbilical vein endothelial cells ( = HUVEC<sup>p</sup>), human dermal fibroblasts (HDF), HepG2, and HeLa cells were incubated with 120 nM unlabeled purified rhDAO-WT and various HBM mutants and detected with rabbit anti-ABP1 antibodies and Alexa Fluor 488 donkey anti-rabbit antibodies after fixation and permeabilization. Immortalized HUVEC/TERT2 ( = HUVEC<sup>i</sup>) and human dermal microvascular endothelial cells (HDMVEC/TERT164-B = HDMVEC<sup>i</sup>) were incubated with 120 nM and extravillous trophoblasts (EVT) with 60 nM Alexa488-labeled rhDAO-WT and rhDAO-R568S/R571T; Scale bar = 20 μm. (<bold>B</bold>) Cells were incubated with 30 nM Alexa488-labeled rhDAO-WT and rhDAO-R568S/R571T mutant (no DAO added = negative control), washed, and analyzed flow cytometrically (500 cells per sample). Background corrected mean median values ± standard error of the mean (SEM) are shown (n = 4 biological replicates, two individual experiments in duplicate). (<bold>C</bold>) 10<sup>6</sup> SK-Hep1 and 5 × 10<sup>5</sup> HUVEC/TERT2 cells were incubated with 120 nM and 60 nM rhDAO-WT and three HBM mutants. The cell lysates were analyzed for DAO uptake using western blotting. β-Actin was used as an internal standard. (<bold>D</bold>) After background subtraction, rhDAO band intensities were corrected against β-Actin and normalized against the rhDAO-WT band. The mean ± SEM of two individual experiments with SK-Hep1 cells and one experiment with HUVEC/TERT2 cells are shown. (<bold>A–D</bold>) Incubations were performed for 60 min at 37°C. FI: fluorescence intensity; AU: arbitrary units.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Statistical evaluation of flow cytometry data is summarized in <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-68542-fig3-data1-v2.docx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Raw unedited western blots are presented in <xref ref-type="fig" rid="fig3">Figure 3C</xref>.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-68542-fig3-data2-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68542-fig3-v2.tif"/></fig></fig-group><p>In flow cytometric analyses, the reduction in fluorescence of the double mutant rhDAO-R568S/R571T ranged from 67% in SK-Hep1 to 85% in PODO/TERT256 cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The decrease in fluorescence intensity was statistically significant for all cell lines (p-value&lt;0.05; <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>).</p><p>Western blot analyses of SK-Hep1 and HUVEC/TERT2 cells incubated with rhDAO-WT and three HBM mutants support the results obtained using fluorescence microscopy and flow cytometry. The mean (SEM) uptake of the single mutant was reduced by only 29–71% (9%), while the band intensities of rhDAO-R568S/R571T and rhDAO-R568S/K575T decreased more than fivefold to 17% (5%) and 18% (3%), respectively (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>).</p></sec><sec id="s3-4"><title>Clearance of HBM mutants is strongly decreased compared to wildtype DAO in rats and mice</title><p>After demonstrating reduced in vitro cellular uptake using the HBM mutants, pharmacokinetic parameters were determined in rats and mice. The data are summarized in <xref ref-type="table" rid="table2">Table 2</xref>. The double mutant rhDAO-R568S/R571T generated the highest area under the curve (AUC), followed by rhDAO-R568S and rhDAO-R568S/K575T (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). We also tested an rhFc-DAO wildtype fusion protein and the corresponding rhFc-DAO-R568S/R571T mutant confirming the improved pharmacokinetic parameters (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Recombinant human diamine oxidase (rhDAO) heparin-binding motif (HBM) mutants show strongly reduced clearance compared to the wildtype protein in rats and mice.</title><p>(<bold>A, B</bold>) Reduced clearance of HBM mutants in rats. Means of the measured values ± standard deviation (SD) after administration of 1 mg/kg purified rhDAO: (<bold>A</bold>) WT (n = 9; □), -R568S (n = 4; ■), -R568S/R571T (n = 5; ●), -R568S/K575T (n = 4; △); (<bold>B</bold>) rhFcDAO (n = 6; □), Fc-R568S/R571T (n = 4; ●). (<bold>C, D</bold>) rhDAO-R568S/R571T mutant increases the area under the curve (AUC) more than 15-fold compared to wildtype rhDAO after intravenous and intraperitoneal injection into mice. (<bold>C</bold>) rhDAO-WT (□) and rhDAO-R568S/R571T (●) were injected at 1 mg/kg into the tail vein of C57BL6 mice with a body weight of about 20 g. The mean (n = 3–4 mice per time point) ± SD are shown. (<bold>D</bold>) rhDAO-WT and rhDAO-R568S/R571T mutant were injected intraperitoneally at 1 mg/kg in mice with a body weight of 21 g. Each time point represents the mean of 3 mice, and therefore in total 15 mice with WT and 15 mice with rhDAO-R568S/R571T were used. The means ± SD are shown. n: number of animals.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68542-fig4-v2.tif"/></fig><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Recombinant human diamine oxidase (rhDAO) heparin-binding motif mutants eliminate the fast α-distribution half-life and strongly reduce clearance in rats and mice.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="bottom">rhDAO</th><th align="left" colspan="8" valign="bottom">Rats IV</th></tr><tr><th align="left" colspan="2" valign="bottom">AUC (µg/mL/min)<sup><xref ref-type="table-fn" rid="table2fn1">*</xref><xref ref-type="table-fn" rid="table2fn2">†</xref></sup></th><th align="left" colspan="2" valign="bottom">Fold increase</th><th align="left" colspan="2" valign="bottom">t<sub>1/2</sub> α (min)</th><th align="left" colspan="2" valign="bottom">t<sub>1/2</sub> β (min)</th></tr></thead><tbody><tr><td align="left" valign="bottom">WT</td><td align="char" char="." colspan="2" valign="bottom">116</td><td align="char" char="." colspan="2" valign="bottom">1.0</td><td align="char" char="." colspan="2" valign="bottom">3.7</td><td align="char" char="." colspan="2" valign="bottom">250</td></tr><tr><td align="left" valign="bottom">R568S</td><td align="char" char="." colspan="2" valign="bottom">1531</td><td align="char" char="." colspan="2" valign="bottom">13.2</td><td align="left" colspan="2" valign="bottom">na</td><td align="char" char="." colspan="2" valign="bottom">294</td></tr><tr><td align="left" valign="bottom">R568S/R571T</td><td align="char" char="." colspan="2" valign="bottom">3788</td><td align="char" char="." colspan="2" valign="bottom">32.6</td><td align="left" colspan="2" valign="bottom">na</td><td align="char" char="." colspan="2" valign="bottom">353</td></tr><tr><td align="left" valign="bottom">R568S/K575T</td><td align="char" char="." colspan="2" valign="bottom">2113</td><td align="char" char="." colspan="2" valign="bottom">18.2</td><td align="char" char="." colspan="2" valign="bottom">42</td><td align="char" char="." colspan="2" valign="bottom">361</td></tr><tr><td align="left" valign="bottom">Fc-WT</td><td align="char" char="." colspan="2" valign="bottom">69</td><td align="char" char="." colspan="2" valign="bottom">1.0</td><td align="char" char="." colspan="2" valign="bottom">1.7</td><td align="char" char="." colspan="2" valign="bottom">120</td></tr><tr><td align="left" valign="bottom">Fc-R568S/R571T</td><td align="char" char="." colspan="2" valign="bottom">2723</td><td align="char" char="." colspan="2" valign="bottom">39.5</td><td align="left" colspan="2" valign="bottom">na</td><td align="char" char="." colspan="2" valign="bottom">268</td></tr><tr><td align="left" rowspan="2" valign="bottom"> </td><td align="left" colspan="4" valign="bottom">Mice IV</td><td align="left" colspan="4" valign="bottom">Mice IP</td></tr><tr><td align="left" valign="bottom">AUC (µg/mL/min)<sup><xref ref-type="table-fn" rid="table2fn2">†</xref></sup></td><td align="left" colspan="2" valign="bottom">Fold increase</td><td align="left" valign="bottom">t<sub>1/2</sub> (min) <xref ref-type="table-fn" rid="table2fn3">‡</xref><sup> <xref ref-type="table-fn" rid="table2fn3">‡</xref></sup></td><td align="left" valign="bottom">AUC (µg/mL/min)<sup> <xref ref-type="table-fn" rid="table2fn4">§</xref> <xref ref-type="table-fn" rid="table2fn3">‡</xref></sup></td><td align="left" colspan="2" valign="bottom">Fold increase</td><td align="left" valign="bottom">t<sub>1/2</sub> (min) <xref ref-type="table-fn" rid="table2fn3">‡</xref><sup><xref ref-type="table-fn" rid="table2fn1">*</xref> <xref ref-type="table-fn" rid="table2fn4">§</xref></sup></td></tr><tr><td align="left" valign="bottom">WT</td><td align="char" char="." valign="bottom">76</td><td align="char" char="." colspan="2" valign="bottom">1.0</td><td align="char" char="." valign="bottom">76.1</td><td align="char" char="." valign="bottom">41.2</td><td align="char" char="." colspan="2" valign="bottom">1.0</td><td align="char" char="." valign="bottom">200</td></tr><tr><td align="left" valign="bottom">R568S/R571T</td><td align="char" char="." valign="bottom">1468</td><td align="char" char="." colspan="2" valign="bottom">19.4</td><td align="char" char="." valign="bottom">192.1</td><td align="char" char="." valign="bottom">666.3</td><td align="char" char="." colspan="2" valign="bottom">16.2</td><td align="char" char="." valign="bottom">394</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><label>*</label><p>Calculated from 5 to 1440 min.</p></fn><fn id="table2fn2"><label>†</label><p>Calculated from 10 to 1680 min.</p></fn><fn id="table2fn3"><label>‡</label><p>Calculated from 60 to 1680 min.</p></fn><fn id="table2fn4"><label>§</label><p>Calculated from 0 to 1440 min.</p></fn><fn><p>AUC = area under the curve; IV = intravenous; IP = intraperitoneal; na = not applicable.</p></fn></table-wrap-foot></table-wrap><p>The most promising variant rhDAO-R568S/R571T was also tested in mice, and the data support the rat data with more than 15-fold increases in the AUC after intravenous or intraperitoneal administration (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref> and <xref ref-type="table" rid="table2">Table 2</xref>).</p><p>The rhDAO-R568S/R571T mutant with and without a 100-fold molar excess of HMWH degraded histamine as efficiently as wildtype DAO using 1 µg/mL or 6 nM enzyme concentration (<xref ref-type="fig" rid="fig5">Figure 5A</xref> compared to WT in <xref ref-type="fig" rid="fig1">Figure 1A</xref>). No significant differences in enzymatic activity could be detected comparing rhDAO-WT and -R568S/R571T mutant at concentrations of 0.7, 2, and 6 nM using a different assay format (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). After intravenous administration of rhDAO-R568S/R571T, rhDAO-R568S/K575T, and the Fc fusion protein Fc-R568S/R571T, the corresponding DAO activity could be readily measured for 28 hr (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Diamine oxidase concentrations and activities are highly correlated with R<sup>2</sup> values of &gt;96% (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Recombinant human diamine oxidase (rhDAO) heparin-binding motif (HBM) mutants are enzymatically fully active in vitro and in vivo.</title><p>(<bold>A</bold>) Purified rhDAO-R568S/R571T mutant rapidly and completely degrades histamine. 6 nM rhDAO-R568S/R571T with and without 100× high molecular weight heparin (HMWH) (600 nM) were incubated with 100 ng/mL histamine in 1% human serum albumin-phosphate buffered saline (HSA-PBS) and EDTA plasma of a healthy volunteer for 60 min at 37°C. Histamine concentrations were determined in duplicate. Plasma: △; plasma with 100× HMWH: ◇; HSA-PBS: ○; HSA-PBS with 100× HMWH: □. (<bold>B–D</bold>) rhDAO HBM mutants are enzymatically active in rats. Means of the measured values ± standard error of the mean (SEM) using 1 mg/kg rhDAO-R568S/R571T (<bold>B</bold>, n = 3; R<sup>2</sup> = 94.8% with p-value&lt;0.001, linear regression) and rhFcDAO-R568S/R571T (<bold>D</bold>, n = 3; R<sup>2</sup> = 98% with p-value&lt;0.001, linear regression) and two individually plotted measurements of rhDAO-R568S/K575T (<bold>C</bold>); rhDAO concentration (ng/mL; □ and ○) and activity (relative fluorescence units [RFU]; ■ and ●); RFU data downscaled by a factor 50 in panels (<bold>B</bold>) and (<bold>C</bold>) and by 100 in (<bold>D</bold>) for easier presentation. n: number of animals.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68542-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Recombinant human diamine oxidase (rhDAO) antigen concentrations and activity are highly correlated in rat plasma.</title><p>Means of the measured values using 1 mg/kg rhDAO-R568S/R571T (<bold>A</bold>, n = 3) and Fc-rhDAO-R568S/R571T (<bold>C</bold>, n = 3) and two individually plotted measurements of rhDAO-R568S/K575T (<bold>B</bold>); relative fluorescence units (RFU) data downscaled by factor 50 in panels (<bold>A</bold>) and (<bold>B</bold>) and by factor 100 in (<bold>C</bold>). n: number of animals.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68542-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>The enzymatic activity of rhDAO-R568S/R571T is comparable to rhDAO-WT.</title><p>Enzymatic activity of rhDAO-WT (□) and rhDAO-R568S/R571T (●) at 0.7 nM, 2 nM, and 6 nM was measured as published (<xref ref-type="bibr" rid="bib7">Boehm et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Boehm et al., 2017</xref>). Means ± standard deviation (SD) of duplicate measurements are shown. RLU: relative light units; rhDAO: recombinant human diamine oxidase.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68542-fig5-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s3-5"><title>In silico analysis of heparin binding indicates a key role of the conserved R568 residue</title><p>Comparison of the HBM in 87 DAO <italic>Mammalia</italic> sequences showed an overall sequence identity of 68% at positions R568 to K575, with 89, 49, and 67% conservation at positions R568, R571, and K575, respectively. In the alignment of 15 HBM sequences from old world monkeys, great apes, and humans, residues from R568 to P574 are 100% conserved. At the single variable position 575, 3 of the 15 sequences have a lysine (20%), but it is conservatively substituted by an arginine in 11 sequences (73%). The evolutionary conservation analysis is summarized in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p>The symmetric HBM on top of the DAO dimer is composed of the residues <sup>568</sup>RFKRKLPK<sup>575</sup> from both chains (<xref ref-type="fig" rid="fig6">Figure 6A</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>), with 10 out of 16 residues (63%) positively charged. The experimental results demonstrated that R568 is critical for heparin binding. The replacement of R568 by a serine (<xref ref-type="fig" rid="fig6">Figure 6B</xref>) was predicted to strongly decrease the binding affinity, while the variants R571T (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) and K575T (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B and C</xref>) were predicted to be associated with lower binding energy changes (<xref ref-type="table" rid="table3">Table 3</xref>), supporting the experimental binding data using heparin-sepharose (<xref ref-type="table" rid="table1">Table 1</xref>). The squared correlation coefficient from regression analysis using affinity predictions and measured salt elution concentrations was 93% (p-value 0.0088) including wildtype and four HBM mutants but excluding the triple mutant (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Structural analysis of the heparin-binding motif (HBM) in the 3D models for the R568S, R571T, and R568S/R571T mutants compared with the crystal structure of hDAO-WT.</title><p>(<bold>A</bold>) Top view of the HBM in hDAO-WT. R568 and R571 (green sticks) are the key residues in the positively charged HBM formed by arginines and lysines from both chains in the hDAO-WT dimer. Intramolecular interactions formed by R571 stabilize the HBM. (<bold>B</bold>) Top view of the HBM in hDAO-R568S dimer. The positively charged area is reduced around S568s in the R568S mutant compared to hDAO-WT (<bold>A</bold>). (<bold>C</bold>) Top view of the HBM in hDAO-R571T. The stabilizing interactions formed by R571 in hDAO-WT (<bold>A</bold>) are lost, and positive patches around T571s are reduced in hDAO-R571T. (<bold>D</bold>) Complex of hDAO-WT dimer with heparin hexasaccharide, sliced side view. R568s form hydrogen bonds with heparin hexasaccharide. (<bold>E</bold>) Complex of hDAO-R568S/R571T dimer with heparin hexasaccharide, sliced side view. In the R568S/R571T mutant, the positively charged surface patches and the stabilizing interactions are lost. Red color corresponds to the negatively charged surface, blue color indicates positively charged regions. hDAO: human diamine oxidase.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68542-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Structural analysis of the heparin-binding motif (HBM) in 3D models of the K575T, K570G/R571Q/K572T, and R568S/R571T mutants versus the crystal structure of hDAO-WT.</title><p>(<bold>A</bold>) HBM in hDAO-WT, top view. (<bold>B</bold>) Complex of hDAO-WT (left) and hDAO-K575T (right) dimers with heparin hexasaccharide, sliced side view. Change of lysine to threonine leads to a dramatic decrease in the positively charged surface inside the HBM. (<bold>C</bold>) Local interaction networks of K575 (chain A) in hDAO-WT and the corresponding site with T575 (chain B) of hDAO-K575T show that the mutation eliminates stabilizing hydrogen bonds. (<bold>D</bold>) Local interaction network of R568 is shown in chain A and R571 – in chain B of hDAO-WT. R568 interacts with heparin hexasaccharide, and R571 establishes multiple interactions with other residues stabilizing the HBM. (<bold>E</bold>) Local interaction networks are shown for S568 in chain A and T571 – in chain B of hDAO-R568S/R571T. The double mutation leads to an evident disruption of the hydrogen bonding network due to R571T mutation and loss of interactions with the heparin hexasaccharide due to R568S mutation. (<bold>F</bold>) Local interaction networks of K570, R571, and K572 (chain A) in hDAO-WT compared to the corresponding site in hDAO-K570G/R571Q/K572T (chain B). The triple mutation reduces the number of favorable interactions with other binding site residues and heparin hexasaccharide. (<bold>G</bold>) Top view of hDAO-WT compared to the K570G/R571Q/K572T triple mutant (chain B). The surface charge of the HBM changes from positive to negative charge in the triple mutant. Red color corresponds to the negatively charged surface, blue color indicates positively charged regions. hDAO: human diamine oxidase.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68542-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Regression analysis of in silico affinity change estimations and measured heparin-sepharose salt elution concentrations of various heparin-binding motif (HBM) mutants.</title><p>Regression analysis of predicted free energy changes in heparin affinity and the NaCl concentrations necessary for the elution from heparin-sepharose of the HBM mutants rhDAO-R568S, rhDAO-K575T, rhDAO-R568S/R571T, and rhDAO-R568S/K575T versus rhDAO-WT (0 affinity; 372 mM NaCl). The rhDAO-K570G/R571Q/K572T triple mutant corresponding to the HBM in guinea pig, dog, rat, mouse, and Chinese hamster proteins was excluded (<bold>A</bold>, p-value 0.0088), or included (<bold>B</bold>, p-value 0.08) in the calculations.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68542-fig6-figsupp2-v2.tif"/></fig></fig-group><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Predicted free energy changes in the human diamine oxidase (hDAO) dimer by mutation of the heparin-binding motif (HBM).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="top">rhDAO mutant variant</th><th align="left" colspan="2" valign="top">Stability</th><th align="left" colspan="2" valign="top">Affinity</th></tr><tr><th align="left" valign="top">∆∆G (kcal/mol)</th><th align="left" valign="top"/><th align="left" valign="top">∆∆G (kcal/mol)</th><th align="left" valign="top"/></tr></thead><tbody><tr><td align="left" valign="top">R568S</td><td align="char" char="." valign="top">+0.29</td><td align="left" rowspan="7" valign="top"/><td align="char" char="." valign="top">+3.50</td><td align="left" rowspan="7" valign="top"/></tr><tr><td align="left" valign="top">R571T</td><td align="char" char="." valign="top">+0.73</td><td align="char" char="." valign="top">+1.96</td></tr><tr><td align="left" valign="top">K575T</td><td align="char" char="." valign="top">+2.13</td><td align="char" char="." valign="top">+0.55</td></tr><tr><td align="left" valign="top">R568S/R571T</td><td align="char" char="." valign="top">+0.60</td><td align="char" char="." valign="top">+5.21</td></tr><tr><td align="left" valign="top">R568S/K575T</td><td align="char" char="." valign="top">+2.42</td><td align="char" char="." valign="top">+3.93</td></tr><tr><td align="left" valign="top">R571T/K575T</td><td align="char" char="." valign="top">+2.86</td><td align="char" char="." valign="top">+2.52</td></tr><tr><td align="left" valign="top">K570G/R571Q/K572T<xref ref-type="table-fn" rid="table3fn2">*</xref></td><td align="char" char="." valign="top">+1.53</td><td align="char" char="." valign="top">+7.77</td></tr></tbody></table><table-wrap-foot><fn><p>The plus sign (+) in the ‘Stability’ column indicates the destabilizing effect on the 3D protein structure, while the plus sign (+) in the ‘Affinity’ column means reduced affinity to heparin hexasaccharide compared to wildtype hDAO. A higher value indicates higher effect on stability or affinity.</p></fn><fn id="table3fn2"><label>*</label><p>Corresponds to the HBM in guinea pig, dog, rat, mouse, and Chinese hamster.</p></fn></table-wrap-foot></table-wrap><p>In both rhDAO chains, R568 forms ionic interactions and hydrogen bonds with the sulfate groups of the heparin hexasaccharide (<xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>). These interactions are absent in the R568S mutant (<xref ref-type="fig" rid="fig6">Figure 6E</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>). The R571 residue has a role in the overall architecture of the HBM since its guanidinium group forms intra-chain hydrogen bonds (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>), which are lost in the R571T mutant (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>). The negligible effect of K575T change on binding affinity can be attributed to its deep location and long distance from the heparin hexasaccharide. The destabilizing effect (<xref ref-type="table" rid="table3">Table 3</xref>) likely results from the loss of favorable intramolecular interactions formed by K575 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B and C</xref>). Although the triple mutant K570G/R571Q/K572T (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F and G</xref>) showed the lowest predicted affinity of all mutants, binding to heparin-sepharose was stronger compared to R568S/R571T (<xref ref-type="table" rid="table1">Table 1</xref>). This discrepancy might be explained by the additive nature of the energy change calculating algorithm, which is functionally optimized for single and double point mutations and likely overestimates the effects of triple mutations (<xref ref-type="bibr" rid="bib44">Spassov and Yan, 2013</xref>). Due to the surface position of R568, K570, R571, and K572, the effects of their mutations on the structural stability, even in the case of the triple mutant, are predicted to be lower (<xref ref-type="table" rid="table3">Table 3</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F and G</xref>).</p></sec></sec><sec id="s27" sec-type="discussion"><title>Discussion</title><p>Plasma histamine concentrations of at least 500 ng/mL (4.5 µM) were measured in a systemic mastocytosis patient following gastrointestinal endoscopy (<xref ref-type="bibr" rid="bib11">Desborough et al., 1990</xref>). We recently published data on the circulatory collapse in a mastocytosis patients with 70 ng/mL plasma histamine (<xref ref-type="bibr" rid="bib6">Boehm et al., 2019</xref>). Histamine concentrations in another systemic mastocytosis patient increased from 10 ng/mL to 35 ng/mL over a few hours. The patient developed severe clinical symptoms despite high-dose treatment with the histamine receptor 1 antagonist diphenhydramine and the histamine receptor 2 antagonist ranitidine (<xref ref-type="bibr" rid="bib6">Boehm et al., 2019</xref>). Despite treatment with histamine receptor antagonists up to four times the approved dose and the use of additional medications, approximately 70% of mastocytosis patients define themselves as disabled in accordance with standard definitions of disability (<xref ref-type="bibr" rid="bib22">Hermine et al., 2008</xref>). Finally, 25–33% of chronic urticaria patients are resistant to histamine receptor antagonists (<xref ref-type="bibr" rid="bib48">van den Elzen et al., 2017</xref>). Why is the efficacy of histamine receptor blockers during severe anaphylaxis, MC activation, or chronic urticaria limited?</p><p><xref ref-type="bibr" rid="bib24">Kaliner et al., 1982</xref> and <xref ref-type="bibr" rid="bib33">Owen et al., 1982</xref> described that in healthy volunteers two combinations of histamine receptor antagonists, cimetidine with hydroxyzine and cimetidine with chlorpheniramine, respectively, were only able to sufficiently block symptom development until systemic histamine concentrations of approximately 6 ng/mL were reached. Single treatments with either histamine receptor 1 or 2 antagonist were minimally protective. The 6 ng/mL threshold is only three to four times higher compared to no treatment and 20-fold below the mean histamine concentration of 140 ng/mL reached during severe anaphylaxis after an insect sting challenge (<xref ref-type="bibr" rid="bib49">van der Linden et al., 1992</xref>). Clinically relevant hypotension starts to develop at levels above 5 ng/mL histamine. We can only conclude that histamine receptor antagonists are easily overwhelmed during anaphylaxis, MC activation, and even chronic urticaria.</p><p>Herein we show for the first time that rhDAO can rapidly and completely degrade pathophysiologically relevant histamine concentrations of 100 ng/mL. Nevertheless, in rodents wildtype rhDAO showed a very fast α-distribution half-life, rendering it unsuitable for further development as a new and first-in-class biopharmaceutical. The fast clearance in vivo was independent of the asialoglycoprotein- and mannose-receptors, the two well-characterized protein clearance systems. Cellular internalization in vitro into various cell lines was dependent on the interaction with HS glycosaminoglycans and was blocked by excess heparin (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>).</p><p>We therefore mutated the putative HBM (<xref ref-type="bibr" rid="bib32">Novotny et al., 1994</xref>) and unequivocally demonstrated that this 2 × 8 linear amino acid stretch, which forms a distinct positively charged ring structure, mediates not only cellular internalization but also rapid clearance in rodents. Mutations in the HBM eliminated heparin binding. Importantly, DAO activity of wildtype and various mutants was indistinguishable. The wildtype DAO dimer sequence excluding the HBM contains 84 arginine and 42 lysines residues, many of which are surface-exposed, but none of these positively charged residues seems critically involved in heparin binding. BLAST analysis of the RFKRKLPK motif revealed a high sequence identity of R568 and K575 in all mammalian DAO sequences analyzed. Our experimental data suggest the essential role of the conserved R568 residue in the heparin binding of DAO, which is supported by the in silico modeling comparing the interactions of wildtype and mutant DAO with the docked heparin hexasaccharide. While the single mutation of this amino acid was sufficient to achieve a comparable decrease in binding to heparin-sepharose versus the double mutants, a strong reduction of cellular uptake was only accomplished with the double mutants. Neither ITC nor BLI detected any interaction of rhDAO-R568S/R571T with HMWH and HS. In silico modeling supports not only the biochemical and cellular in vitro but also the rats and mice in vivo data. The HBM mutant with the best in vivo pharmacokinetic profile, rhDAO-R568S/R571T, showed low increases in the Gibbs free energy concerning stability but demonstrated a strong decrease in affinity. The correlation coefficient comparing in silico-estimated affinity data changes with experimental heparin-sepharose in vitro binding data of wildtype and four HBM mutants is 0.93 with a p-value of less than 0.01.</p><p>Incubation of various cell lines with rhDAO-R568S/R571T did not completely abrogate cellular uptake, but flow cytometry and western blot analyses showed that at least 15% of the internalization cannot be attributed to HSPG interaction. This is in accordance with our previous study, where a 100-fold excess of HMWH over rhDAO-WT could not reduce the uptake below 5 and 25% in various cell lines (<xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>). In the same study, we observed the presence of high-affinity-binding sites in HUVEC/TERT2 cells in addition to the low-affinity HSPG-binding sites. Similarly, cellular binding of amyloid protein precursor and fibroblast growth factor 2 is predominantly mediated by low-affinity HSPG interactions that serve as scaffolds or co-receptors that promote and/or stabilize the formation of complexes of proteins and high-affinity receptors (<xref ref-type="bibr" rid="bib12">Duchesne et al., 2012</xref>; <xref ref-type="bibr" rid="bib36">Reinhard et al., 2013</xref>; <xref ref-type="bibr" rid="bib45">Thompson et al., 1994</xref>; <xref ref-type="bibr" rid="bib52">Xu and Esko, 2014</xref>). Since the HS-binding sites can outnumber the amount of protein-specific receptors by 100- to 1000-fold (<xref ref-type="bibr" rid="bib12">Duchesne et al., 2012</xref>), it is not surprising that only a low proportion of binding can be attributed to the latter. These high-affinity-binding sites might be responsible for the β-elimination of the heparin-binding mutants. Our data are in agreement with this hypothesis. While the clearance of more than 90% of the rhDAO-WT dose in the fast α-elimination phase of less than 5 min is fully abrogated by the double mutation of R568 and R571, the long β-elimination phase of about 6 hr is more or less unchanged. It is therefore likely that this second phase is determined by a different clearance mechanism independent of the heparin-binding domain.</p><p>It will be interesting to study the distribution of wildtype versus HBM mutant DAO variants after intravenous infusion in animal models because it is not clear which cells or organs remove 90% of the wildtype DAO protein within a few minutes. The liver has been considered mainly responsible for elimination of DAO, but in view of the dependence of DAO internalization on HS, endothelial cells throughout the circulatory system could rapidly remove DAO (<xref ref-type="bibr" rid="bib13">D’Agostino et al., 1986</xref>). These cells abundantly express HSPGs and are able to bind and internalize DAO in vitro (<xref ref-type="bibr" rid="bib16">Fuster and Wang, 2010</xref>; <xref ref-type="bibr" rid="bib20">Gludovacz et al., 2020</xref>).</p><p>The half-life of the HBM mutant rhDAO-R568S/R571T is approximately 6 hr in rodents, which is certainly sufficient for the treatment of most human anaphylaxis events. The rodent HBM does not contain the central <sup>570</sup>KRK<sup>572</sup> sequence present in humans but instead <sup>570</sup>GQT<sup>572</sup> and therefore the half-life in humans could be longer, assuming that the 6 hr half-life is still at least partially determined by the same HS internalization process. The rodent HBM is only weakly heparin binding.</p><p>In conclusion, mutations in the proposed and now proven HBM converted rhDAO wildtype protein into a candidate for a first-in-class histamine receptor-independent biopharmaceutical for the rapid and complete elimination of excessive histamine. First clinical indications might be diseases where it has been known for decades that histamine plays an important pathophysiological role. These include anaphylaxis, MC activation syndrome, mastocytosis, and chronic urticaria. Nevertheless, the use of HBM mutants will also allow clinical proof-of-concept studies in other diseases, where the involvement of histamine and MCs is suspected, but where clinical studies with available histamine receptor antagonists were unsuccessful. No drug blocking histamine receptor 4 has been approved to date. This group of diseases includes, amongst others, asthma, atopic dermatitis, infusion reactions, different forms of pruritus, and inflammatory bowel disease. rhDAO with HBM mutations might overcome the current limitations of histamine receptor antagonists for the treatment of diseases that lead to life-threatening histamine exposure but are resistant to conventional treatment modalities.</p></sec></body><back><sec id="s28" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>is named as an inventor with The Medical University of Vienna and the University of Natural Resources and Life Sciences of a patent describing the rhDAO heparin-binding motif mutants presented herein (patent pending WO2020169577A1)</p></fn><fn fn-type="COI-statement" id="conf2"><p>none</p></fn><fn fn-type="COI-statement" id="conf3"><p>None</p></fn><fn fn-type="COI-statement" id="conf4"><p>is named as an inventor with The Medical University of Vienna and the University of Natural Resources and Life Sciences of a patent describing the rhDAO heparin-binding motif mutants presented herein (patent pending WO2020169577A1).</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation, Validation</p></fn><fn fn-type="con" id="con10"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Funding acquisition, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Funding acquisition, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Supervision, Validation, Visualization, Writing - original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The experimental protocols for the treatment of rats and mice were approved by the local Animal Welfare Committee and the Federal Ministry of Science, Research and Economy (GZ 66.009/0152-WF/V/3b/2014) and conducted in full accordance with the ARRIVE guidelines.</p></fn></fn-group></sec><sec id="s29" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>The evolutionary conservation analysis of the diamine oxidase (DAO) heparin-binding motif is summarized in Supplementary file 1.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-68542-supp1-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-68542-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s30" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2 and 3.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank Evercyte GmbH for providing various cell lines for the study. Irene Schaffner and Jakob Wallner of the Core Facility 'Biomolecular &amp; Cellular Analysis' (University of Natural Resources and Life Sciences) are greatly acknowledged for their support with automated ITC and BLI analyses and the Core Facility 'Multiscale Imaging' (University of Natural Resources and Life Sciences) for technical support with microscopy. We thank Leander Sützl for the selection and alignment of mammalian DAO sequences. We are grateful to the bioinformatics (J.V. Lehtonen), translational activities and structural biology (FINStruct) infrastructure support from Biocenter Finland and CSC IT Center for Science for computational infrastructure support at the Structural Bioinformatics Laboratory (SBL), Å̊bo Akademi University. SBL is part of the NordForsk Nordic POP (Patient Oriented Products), the Solutions for Health strategic area of Åbo Akademi University, and the InFlames Flagship program of the Academy of Finland on inflammation, cancer and infection, University of Turku and Åbo Akademi University. We are indebted to Sarah Ely for the final polish in the proper usage of the English language. The publication fees were covered by the BOKU Vienna Open Access Publishing Fund.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashina</surname><given-names>K</given-names></name><name><surname>Tsubosaka</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Omori</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Hori</surname><given-names>M</given-names></name><name><surname>Ozaki</surname><given-names>H</given-names></name><name><surname>Murata</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Histamine induces vascular hyperpermeability by increasing blood flow and endothelial barrier disruption in vivo</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0132367</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0132367</pub-id><pub-id pub-id-type="pmid">26158531</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>NA</given-names></name><name><surname>Sept</surname><given-names>D</given-names></name><name><surname>Joseph</surname><given-names>S</given-names></name><name><surname>Holst</surname><given-names>MJ</given-names></name><name><surname>McCammon</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Electrostatics of nanosystems: application to microtubules and the ribosome</article-title><source>PNAS</source><volume>98</volume><fpage>10037</fpage><lpage>10041</lpage><pub-id pub-id-type="doi">10.1073/pnas.181342398</pub-id><pub-id pub-id-type="pmid">11517324</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbry</surname><given-names>P</given-names></name><name><surname>Champe</surname><given-names>M</given-names></name><name><surname>Chassande</surname><given-names>O</given-names></name><name><surname>Munemitsu</surname><given-names>S</given-names></name><name><surname>Champigny</surname><given-names>G</given-names></name><name><surname>Lingueglia</surname><given-names>E</given-names></name><name><surname>Maes</surname><given-names>P</given-names></name><name><surname>Frelin</surname><given-names>C</given-names></name><name><surname>Tartar</surname><given-names>A</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Human kidney amiloride-binding protein: cDNA structure and functional expression</article-title><source>PNAS</source><volume>87</volume><fpage>7347</fpage><lpage>7351</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.19.7347</pub-id><pub-id pub-id-type="pmid">2217167</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biebl</surname><given-names>M</given-names></name><name><surname>Klocker</surname><given-names>J</given-names></name><name><surname>Perkmann</surname><given-names>R</given-names></name><name><surname>Kolbitsch</surname><given-names>C</given-names></name><name><surname>Klingler</surname><given-names>P</given-names></name><name><surname>Drasche</surname><given-names>A</given-names></name><name><surname>Klingler</surname><given-names>A</given-names></name><name><surname>Fraedrich</surname><given-names>G</given-names></name><name><surname>Schwelberger</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Heparin-induced diamine oxidase release into the circulation in pigs</article-title><source>Inflammation Research</source><volume>51</volume><fpage>S93</fpage><lpage>S94</lpage><pub-id pub-id-type="doi">10.1007/pl00022465</pub-id><pub-id pub-id-type="pmid">12013428</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>T</given-names></name><name><surname>Pils</surname><given-names>S</given-names></name><name><surname>Gludovacz</surname><given-names>E</given-names></name><name><surname>Szoelloesi</surname><given-names>H</given-names></name><name><surname>Petroczi</surname><given-names>K</given-names></name><name><surname>Majdic</surname><given-names>O</given-names></name><name><surname>Quaroni</surname><given-names>A</given-names></name><name><surname>Borth</surname><given-names>N</given-names></name><name><surname>Valent</surname><given-names>P</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Quantification of human diamine oxidase</article-title><source>Clinical Biochemistry</source><volume>50</volume><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2016.12.011</pub-id><pub-id pub-id-type="pmid">28041932</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>T</given-names></name><name><surname>Reiter</surname><given-names>B</given-names></name><name><surname>Ristl</surname><given-names>R</given-names></name><name><surname>Petroczi</surname><given-names>K</given-names></name><name><surname>Sperr</surname><given-names>W</given-names></name><name><surname>Stimpfl</surname><given-names>T</given-names></name><name><surname>Valent</surname><given-names>P</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients</article-title><source>Allergy</source><volume>74</volume><fpage>583</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1111/all.13663</pub-id><pub-id pub-id-type="pmid">30418682</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>T</given-names></name><name><surname>Karer</surname><given-names>M</given-names></name><name><surname>Gludovacz</surname><given-names>E</given-names></name><name><surname>Petroczi</surname><given-names>K</given-names></name><name><surname>Resch</surname><given-names>M</given-names></name><name><surname>Schuetzenberger</surname><given-names>K</given-names></name><name><surname>Klavins</surname><given-names>K</given-names></name><name><surname>Borth</surname><given-names>N</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Simple, sensitive and specific quantification of diamine oxidase activity in complex matrices using newly discovered fluorophores derived from natural substrates</article-title><source>Inflammation Research</source><volume>69</volume><fpage>937</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1007/s00011-020-01359-5</pub-id><pub-id pub-id-type="pmid">32488317</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busby</surname><given-names>TF</given-names></name><name><surname>Argraves</surname><given-names>WS</given-names></name><name><surname>Brew</surname><given-names>SA</given-names></name><name><surname>Pechik</surname><given-names>I</given-names></name><name><surname>Gilliland</surname><given-names>GL</given-names></name><name><surname>Ingham</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Heparin binding by Fibronectin module iii-13 involves six discontinuous basic residues brought together to form a cationic cradle</article-title><source>The Journal of Biological Chemistry</source><volume>270</volume><fpage>18558</fpage><lpage>18562</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.31.18558</pub-id><pub-id pub-id-type="pmid">7629186</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chassande</surname><given-names>O</given-names></name><name><surname>Renard</surname><given-names>S</given-names></name><name><surname>Barbry</surname><given-names>P</given-names></name><name><surname>Lazdunski</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The human gene for diamine oxidase, an amiloride binding protein. Molecular cloning, sequencing, and characterization of the promoter</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>14484</fpage><lpage>14489</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(17)36648-6</pub-id><pub-id pub-id-type="pmid">8182053</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claesson-Welsh</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Vascular permeability--the essentials</article-title><source>Upsala Journal of Medical Sciences</source><volume>120</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.3109/03009734.2015.1064501</pub-id><pub-id pub-id-type="pmid">26220421</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desborough</surname><given-names>JP</given-names></name><name><surname>Taylor</surname><given-names>I</given-names></name><name><surname>Hattersley</surname><given-names>A</given-names></name><name><surname>Garden</surname><given-names>A</given-names></name><name><surname>Wolff</surname><given-names>A</given-names></name><name><surname>Bloom</surname><given-names>SR</given-names></name><name><surname>Morgan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Massive histamine release in a patient with systemic mastocytosis</article-title><source>British Journal of Anaesthesia</source><volume>65</volume><fpage>833</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1093/bja/65.6.833</pub-id><pub-id pub-id-type="pmid">2265056</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duchesne</surname><given-names>L</given-names></name><name><surname>Octeau</surname><given-names>V</given-names></name><name><surname>Bearon</surname><given-names>RN</given-names></name><name><surname>Beckett</surname><given-names>A</given-names></name><name><surname>Prior</surname><given-names>IA</given-names></name><name><surname>Lounis</surname><given-names>B</given-names></name><name><surname>Fernig</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Transport of Fibroblast Growth Factor 2 in the Pericellular Matrix Is Controlled by the Spatial Distribution of Its Binding Sites in Heparan Sulfate</article-title><source>PLOS Biology</source><volume>10</volume><elocation-id>e1001361</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001361</pub-id><pub-id pub-id-type="pmid">22815649</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Agostino</surname><given-names>L</given-names></name><name><surname>Ciacci</surname><given-names>C</given-names></name><name><surname>Capuano</surname><given-names>G</given-names></name><name><surname>Daniele</surname><given-names>B</given-names></name><name><surname>D’Argenio</surname><given-names>G</given-names></name><name><surname>Barone</surname><given-names>MV</given-names></name><name><surname>Rodinò</surname><given-names>S</given-names></name><name><surname>Budillon</surname><given-names>G</given-names></name><name><surname>Mazzacca</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Metabolic fate of plasma diamine oxidase: evidence of isolated and perfused rat liver uptake</article-title><source>Digestion</source><volume>34</volume><fpage>243</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1159/000199337</pub-id><pub-id pub-id-type="pmid">3091435</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Agostino</surname><given-names>L</given-names></name><name><surname>Pignata</surname><given-names>S</given-names></name><name><surname>Daniele</surname><given-names>B</given-names></name><name><surname>Ventriglia</surname><given-names>R</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Ferraro</surname><given-names>C</given-names></name><name><surname>Spagnuolo</surname><given-names>S</given-names></name><name><surname>Lucchelli</surname><given-names>PE</given-names></name><name><surname>Mazzacca</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Release of diamine oxidase into plasma by glycosaminoglycans in rats</article-title><source>Biochimica et Biophysica Acta (BBA) - General Subjects</source><volume>993</volume><fpage>228</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/0304-4165(89)90169-4</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmore</surname><given-names>BO</given-names></name><name><surname>Bollinger</surname><given-names>JA</given-names></name><name><surname>Dooley</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Human kidney diamine oxidase: heterologous expression, purification, and characterization</article-title><source>Journal of Biological Inorganic Chemistry</source><volume>7</volume><fpage>565</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1007/s00775-001-0331-1</pub-id><pub-id pub-id-type="pmid">12072962</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuster</surname><given-names>MM</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Endothelial Heparan Sulfate in Angiogenesis</article-title><source>Progress in Molecular Biology and Translational Science</source><volume>93</volume><fpage>179</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/S1877-1173(10)93009-3</pub-id><pub-id pub-id-type="pmid">20807646</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gäng</surname><given-names>V</given-names></name><name><surname>Gaubitz</surname><given-names>W</given-names></name><name><surname>Gunzer</surname><given-names>U</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>Postheparin-diamine oxidase (histaminase) in anaphylaxis</article-title><source>Klinische Wochenschrift</source><volume>53</volume><fpage>285</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1007/BF01469122</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gludovacz</surname><given-names>E</given-names></name><name><surname>Maresch</surname><given-names>D</given-names></name><name><surname>Bonta</surname><given-names>M</given-names></name><name><surname>Szöllösi</surname><given-names>H</given-names></name><name><surname>Furtmüller</surname><given-names>PG</given-names></name><name><surname>Weik</surname><given-names>R</given-names></name><name><surname>Altmann</surname><given-names>F</given-names></name><name><surname>Limbeck</surname><given-names>A</given-names></name><name><surname>Borth</surname><given-names>N</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name><name><surname>Boehm</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Characterization of recombinant human diamine oxidase (rhDAO) produced in Chinese Hamster Ovary (CHO) cells</article-title><source>Journal of Biotechnology</source><volume>227</volume><fpage>120</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2016.04.002</pub-id><pub-id pub-id-type="pmid">27063138</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gludovacz</surname><given-names>E</given-names></name><name><surname>Maresch</surname><given-names>D</given-names></name><name><surname>de</surname><given-names>CL</given-names></name><name><surname>Puxbaum</surname><given-names>V</given-names></name><name><surname>Baier</surname><given-names>LJ</given-names></name><name><surname>Sützl</surname><given-names>L</given-names></name><name><surname>Guédez</surname><given-names>G</given-names></name><name><surname>Grünwald-Gruber</surname><given-names>C</given-names></name><name><surname>Ulm</surname><given-names>B</given-names></name><name><surname>Pils</surname><given-names>S</given-names></name><name><surname>Ristl</surname><given-names>R</given-names></name><name><surname>Altmann</surname><given-names>F</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name><name><surname>Salminen</surname><given-names>TA</given-names></name><name><surname>Borth</surname><given-names>N</given-names></name><name><surname>Boehm</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Oligomannosidic glycans at Asn-110 are essential for secretion of human diamine oxidase</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>1070</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.814244</pub-id><pub-id pub-id-type="pmid">29187599</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gludovacz</surname><given-names>E</given-names></name><name><surname>Schuetzenberger</surname><given-names>K</given-names></name><name><surname>Resch</surname><given-names>M</given-names></name><name><surname>Tillmann</surname><given-names>K</given-names></name><name><surname>Petroczi</surname><given-names>K</given-names></name><name><surname>Vondra</surname><given-names>S</given-names></name><name><surname>Vakal</surname><given-names>S</given-names></name><name><surname>Schosserer</surname><given-names>M</given-names></name><name><surname>Virgolini</surname><given-names>N</given-names></name><name><surname>Pollheimer</surname><given-names>J</given-names></name><name><surname>Salminen</surname><given-names>TA</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name><name><surname>Borth</surname><given-names>N</given-names></name><name><surname>Boehm</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human diamine oxidase cellular binding and internalization in vitro and rapid clearance in vivo are not mediated by n-glycans but by heparan sulfate proteoglycan interactions</article-title><source>Glycobiology</source><volume>31</volume><fpage>444</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwaa090</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>R</given-names></name><name><surname>Thysell</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1973">1973</year><article-title>On the elimination of transfused heparin-induced diamine oxidase (DAO) activity in rabbits</article-title><source>Acta Physiologica Scandinavica</source><volume>88</volume><fpage>342</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1111/j.1748-1716.1973.tb05462.x</pub-id><pub-id pub-id-type="pmid">4201585</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermine</surname><given-names>O</given-names></name><name><surname>Lortholary</surname><given-names>O</given-names></name><name><surname>Leventhal</surname><given-names>PS</given-names></name><name><surname>Catteau</surname><given-names>A</given-names></name><name><surname>Soppelsa</surname><given-names>F</given-names></name><name><surname>Baude</surname><given-names>C</given-names></name><name><surname>Cohen-Akenine</surname><given-names>A</given-names></name><name><surname>Palmérini</surname><given-names>F</given-names></name><name><surname>Hanssens</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Sobol</surname><given-names>H</given-names></name><name><surname>Fraytag</surname><given-names>S</given-names></name><name><surname>Ghez</surname><given-names>D</given-names></name><name><surname>Suarez</surname><given-names>F</given-names></name><name><surname>Barete</surname><given-names>S</given-names></name><name><surname>Casassus</surname><given-names>P</given-names></name><name><surname>Sans</surname><given-names>B</given-names></name><name><surname>Arock</surname><given-names>M</given-names></name><name><surname>Kinet</surname><given-names>JP</given-names></name><name><surname>Dubreuil</surname><given-names>P</given-names></name><name><surname>Moussy</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Case-Control Cohort Study of Patients’ Perceptions of Disability in Mastocytosis</article-title><source>PLOS ONE</source><volume>3</volume><elocation-id>e2266</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002266</pub-id><pub-id pub-id-type="pmid">18509466</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jutel</surname><given-names>M</given-names></name><name><surname>Akdis</surname><given-names>M</given-names></name><name><surname>Akdis</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Histamine, histamine receptors and their role in immune pathology</article-title><source>Clinical and Experimental Allergy</source><volume>39</volume><fpage>1786</fpage><lpage>1800</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2009.03374.x</pub-id><pub-id pub-id-type="pmid">20085595</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaliner</surname><given-names>M</given-names></name><name><surname>Shelhamer</surname><given-names>JH</given-names></name><name><surname>Ottesen</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Effects of infused histamine: correlation of plasma histamine levels and symptoms</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>69</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1016/s0091-6749(82)80005-5</pub-id><pub-id pub-id-type="pmid">6120967</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapila</surname><given-names>Y</given-names></name><name><surname>Doan</surname><given-names>D</given-names></name><name><surname>Tafolla</surname><given-names>E</given-names></name><name><surname>Fletterick</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Three-dimensional structural analysis of fibronectin heparin-binding domain mutations</article-title><source>Journal of Cellular Biochemistry</source><volume>81</volume><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1002/jcb.1095</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilkenny</surname><given-names>C</given-names></name><name><surname>Browne</surname><given-names>W</given-names></name><name><surname>Cuthill</surname><given-names>IC</given-names></name><name><surname>Emerson</surname><given-names>M</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><collab>NC3Rs Reporting Guidelines Working Group</collab></person-group><year iso-8601-date="2010">2010</year><article-title>Animal research: reporting in vivo experiments: the ARRIVE guidelines</article-title><source>British Journal of Pharmacology</source><volume>160</volume><fpage>1577</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00872.x</pub-id><pub-id pub-id-type="pmid">20649561</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klocker</surname><given-names>J</given-names></name><name><surname>Drasche</surname><given-names>A</given-names></name><name><surname>Sattler</surname><given-names>J</given-names></name><name><surname>Bodner</surname><given-names>E</given-names></name><name><surname>Schwelberger</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Postheparin plasma diamine oxidase activity and the anticoagulant effect of heparin</article-title><source>Inflammation Research</source><volume>49</volume><fpage>S53</fpage><lpage>S54</lpage><pub-id pub-id-type="doi">10.1007/PL00000181</pub-id><pub-id pub-id-type="pmid">10864420</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klocker</surname><given-names>J</given-names></name><name><surname>Perkmann</surname><given-names>R</given-names></name><name><surname>Klein-Weigel</surname><given-names>P</given-names></name><name><surname>Mörsdorf</surname><given-names>G</given-names></name><name><surname>Drasche</surname><given-names>A</given-names></name><name><surname>Klingler</surname><given-names>A</given-names></name><name><surname>Fraedrich</surname><given-names>G</given-names></name><name><surname>Schwelberger</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Continuous administration of heparin in patients with deep vein thrombosis can increase plasma levels of diamine oxidase</article-title><source>Vascular Pharmacology</source><volume>40</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.vph.2004.02.002</pub-id><pub-id pub-id-type="pmid">15063833</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laymon</surname><given-names>CW</given-names></name><name><surname>Cumming</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1939">1939</year><article-title>Histaminase in the Treatment of Urticaria and Atopic Dermatitis</article-title><source>The Journal of Investigative Dermatology</source><volume>2</volume><fpage>301</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/jid.1939.26</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname><given-names>AP</given-names></name><name><surname>Hilmer</surname><given-names>KM</given-names></name><name><surname>Collyer</surname><given-names>CA</given-names></name><name><surname>Shepard</surname><given-names>EM</given-names></name><name><surname>Elmore</surname><given-names>BO</given-names></name><name><surname>Brown</surname><given-names>DE</given-names></name><name><surname>Dooley</surname><given-names>DM</given-names></name><name><surname>Guss</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Structure and Inhibition of Human Diamine Oxidase</article-title><source>Biochemistry</source><volume>48</volume><fpage>9810</fpage><lpage>9822</lpage><pub-id pub-id-type="doi">10.1021/bi9014192</pub-id><pub-id pub-id-type="pmid">19764817</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>H</given-names></name><name><surname>Piness</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1940">1940</year><article-title>Histaminase in the treatment of allergy</article-title><source>Journal of the American Medical Association</source><volume>114</volume><fpage>1742</fpage><lpage>1744</lpage><pub-id pub-id-type="doi">10.1001/jama.1940.02810180018006</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novotny</surname><given-names>WF</given-names></name><name><surname>Chassande</surname><given-names>O</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Lazdunski</surname><given-names>M</given-names></name><name><surname>Barbry</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Diamine oxidase is the amiloride-binding protein and is inhibited by amiloride analogues</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>9921</fpage><lpage>9925</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(17)36970-3</pub-id><pub-id pub-id-type="pmid">8144586</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>DA</given-names></name><name><surname>Harvey</surname><given-names>CA</given-names></name><name><surname>Boyce</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Effects of histamine on the circulatory system</article-title><source>Klinische Wochenschrift</source><volume>60</volume><fpage>972</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1007/BF01716957</pub-id><pub-id pub-id-type="pmid">7132245</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pober</surname><given-names>JS</given-names></name><name><surname>Sessa</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inflammation and the Blood Microvascular System</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>7</volume><elocation-id>a016345</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a016345</pub-id><pub-id pub-id-type="pmid">25384307</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2020">2020</year><data-title>R: A language and environment for statistical computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">http://www.r-project.org</ext-link></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhard</surname><given-names>C</given-names></name><name><surname>Borgers</surname><given-names>M</given-names></name><name><surname>David</surname><given-names>G</given-names></name><name><surname>Strooper</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Soluble amyloid-β precursor protein binds its cell surface receptor in a cooperative fashion with glypican and syndecan proteoglycans</article-title><source>Journal of Cell Science</source><volume>126</volume><fpage>4856</fpage><lpage>4861</lpage><pub-id pub-id-type="doi">10.1242/jcs.137919</pub-id><pub-id pub-id-type="pmid">23986479</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson-White</surname><given-names>A</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Olivecrona</surname><given-names>T</given-names></name><name><surname>Beaven</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Binding of diamine oxidase activity to rat and guinea pig microvascular endothelial cells</article-title><source>Comparisons with Lipoprotein Lipase Binding. J Clin Invest</source><volume>76</volume><fpage>93</fpage><lpage>100</lpage></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandström</surname><given-names>J</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Karlsson</surname><given-names>K</given-names></name><name><surname>Marklund</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>19163</fpage><lpage>19166</lpage><pub-id pub-id-type="pmid">8034674</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>CA</given-names></name><name><surname>Rasband</surname><given-names>WS</given-names></name><name><surname>Eliceiri</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NIH Image to ImageJ: 25 years of image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmid">22930834</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="software"><person-group person-group-type="author"><collab>Schrödinger, LLC</collab></person-group><year iso-8601-date="2021">2021</year><data-title>The molecular graphics system</data-title><version designator="Version 2.0">Version 2.0</version><publisher-name>PYMOL</publisher-name><ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/">https://pymol.org/2/</ext-link></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwelberger</surname><given-names>HG</given-names></name><name><surname>Hittmair</surname><given-names>A</given-names></name><name><surname>Kohlwein</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Analysis of tissue and subcellular localization of mammalian diamine oxidase by confocal laser scanning fluorescence microscopy</article-title><source>Inflammation Research</source><volume>47 Suppl 1</volume><elocation-id>Suppl 1:S60-61</elocation-id><pub-id pub-id-type="doi">10.1007/s000110050273</pub-id><pub-id pub-id-type="pmid">9561417</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwelberger</surname><given-names>HG</given-names></name><name><surname>Dieplinger</surname><given-names>H</given-names></name><name><surname>Kohlwein</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Diamine oxidase and catalase are expressed in the same cells but are present in different subcellular compartments in porcine kidney</article-title><source>Inflammation Research</source><volume>48</volume><fpage>81</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s000110050418</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schymkowitz</surname><given-names>J</given-names></name><name><surname>Borg</surname><given-names>J</given-names></name><name><surname>Stricher</surname><given-names>F</given-names></name><name><surname>Nys</surname><given-names>R</given-names></name><name><surname>Rousseau</surname><given-names>F</given-names></name><name><surname>Serrano</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The FoldX web server: an online force field</article-title><source>Nucleic Acids Research</source><volume>33</volume><fpage>W382</fpage><lpage>W388</lpage><pub-id pub-id-type="doi">10.1093/nar/gki387</pub-id><pub-id pub-id-type="pmid">15980494</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spassov</surname><given-names>VZ</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>pH-selective mutagenesis of protein-protein interfaces: in silico design of therapeutic antibodies with prolonged half-life</article-title><source>Proteins</source><volume>81</volume><fpage>704</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1002/prot.24230</pub-id><pub-id pub-id-type="pmid">23239118</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>LD</given-names></name><name><surname>Pantoliano</surname><given-names>MW</given-names></name><name><surname>Springer</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Energetic Characterization of the Basic Fibroblast Growth Factor-Heparin Interaction: Identification of the Heparin Binding Domain</article-title><source>Biochemistry</source><volume>33</volume><fpage>3831</fpage><lpage>3840</lpage><pub-id pub-id-type="doi">10.1021/bi00179a006</pub-id><pub-id pub-id-type="pmid">8142385</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valent</surname><given-names>P</given-names></name><name><surname>Horny</surname><given-names>HP</given-names></name><name><surname>Triggiani</surname><given-names>M</given-names></name><name><surname>Arock</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Clinical and Laboratory Parameters of Mast Cell Activation as Basis for the Formulation of Diagnostic Criteria</article-title><source>International Archives of Allergy and Immunology</source><volume>156</volume><fpage>119</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1159/000323763</pub-id><pub-id pub-id-type="pmid">21576982</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valent</surname><given-names>P</given-names></name><name><surname>Akin</surname><given-names>C</given-names></name><name><surname>Bonadonna</surname><given-names>P</given-names></name><name><surname>Hartmann</surname><given-names>K</given-names></name><name><surname>Brockow</surname><given-names>K</given-names></name><name><surname>Niedoszytko</surname><given-names>M</given-names></name><name><surname>Nedoszytko</surname><given-names>B</given-names></name><name><surname>Siebenhaar</surname><given-names>F</given-names></name><name><surname>Sperr</surname><given-names>WR</given-names></name><name><surname>Oude Elberink</surname><given-names>JNG</given-names></name><name><surname>Butterfield</surname><given-names>JH</given-names></name><name><surname>Alvarez-Twose</surname><given-names>I</given-names></name><name><surname>Sotlar</surname><given-names>K</given-names></name><name><surname>Reiter</surname><given-names>A</given-names></name><name><surname>Kluin-Nelemans</surname><given-names>HC</given-names></name><name><surname>Hermine</surname><given-names>O</given-names></name><name><surname>Gotlib</surname><given-names>J</given-names></name><name><surname>Broesby-Olsen</surname><given-names>S</given-names></name><name><surname>Orfao</surname><given-names>A</given-names></name><name><surname>Horny</surname><given-names>HP</given-names></name><name><surname>Triggiani</surname><given-names>M</given-names></name><name><surname>Arock</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>LB</given-names></name><name><surname>Metcalfe</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome</article-title><source>The Journal of Allergy and Clinical Immunology. In Practice</source><volume>7</volume><fpage>1125</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2019.01.006</pub-id><pub-id pub-id-type="pmid">30737190</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Elzen</surname><given-names>MT</given-names></name><name><surname>van Os-Medendorp</surname><given-names>H</given-names></name><name><surname>van den</surname><given-names>B</given-names></name><name><surname>van den Hurk</surname><given-names>K</given-names></name><name><surname>Kouznetsova</surname><given-names>OI</given-names></name><name><surname>Lokin</surname><given-names>A</given-names></name><name><surname>Laheij-de Boer</surname><given-names>AM</given-names></name><name><surname>Röckmann</surname><given-names>H</given-names></name><name><surname>Bruijnzeel-Koomen</surname><given-names>C</given-names></name><name><surname>Knulst</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria</article-title><source>Clinical and Translational Allergy</source><volume>7</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.1186/s13601-017-0141-3</pub-id><pub-id pub-id-type="pmid">28289538</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Linden</surname><given-names>PW</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>Poortman</surname><given-names>J</given-names></name><name><surname>Vivié-Kipp</surname><given-names>YC</given-names></name><name><surname>Struyvenberg</surname><given-names>A</given-names></name><name><surname>van der Zwan</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>90</volume><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/s0091-6749(06)80017-5</pub-id><pub-id pub-id-type="pmid">1629497</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velicky</surname><given-names>P</given-names></name><name><surname>Windsperger</surname><given-names>K</given-names></name><name><surname>Petroczi</surname><given-names>K</given-names></name><name><surname>Pils</surname><given-names>S</given-names></name><name><surname>Reiter</surname><given-names>B</given-names></name><name><surname>Weiss</surname><given-names>T</given-names></name><name><surname>Vondra</surname><given-names>S</given-names></name><name><surname>Ristl</surname><given-names>R</given-names></name><name><surname>Dekan</surname><given-names>S</given-names></name><name><surname>Fiala</surname><given-names>C</given-names></name><name><surname>Cantonwine</surname><given-names>DE</given-names></name><name><surname>McElrath</surname><given-names>TF</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name><name><surname>Knöfler</surname><given-names>M</given-names></name><name><surname>Boehm</surname><given-names>T</given-names></name><name><surname>Pollheimer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pregnancy-associated diamine oxidase originates from extravillous trophoblasts and is decreased in early-onset preeclampsia</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>6342</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-24652-0</pub-id><pub-id pub-id-type="pmid">29679053</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollin</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Tso</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Nutrients regulate diamine oxidase release from intestinal mucosa</article-title><source>American Journal of Physiology. Regulatory, Integrative and Comparative Physiology</source><volume>275</volume><fpage>R969</fpage><lpage>R975</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.1998.275.4.R969</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Esko</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Demystifying Heparan Sulfate–Protein Interactions</article-title><source>Annual Review of Biochemistry</source><volume>83</volume><fpage>129</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060713-035314</pub-id><pub-id pub-id-type="pmid">24606135</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68542.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mangoni</surname><given-names>Arduino A</given-names></name><role>Reviewing Editor</role><aff><institution>Flinders Medical Centre</institution><country>Australia</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Turnbull</surname><given-names>Jeremy</given-names></name><role>Reviewer</role></contrib><contrib contrib-type="reviewer"><name><surname>Xu</surname><given-names>Ding</given-names></name><role>Reviewer</role><aff><institution>University at Buffalo, SUNY</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The human enzyme diamine oxidase (hDAO) can rapidly degrade histamine, but unfortunately is cleared from blood too rapidly after injection. The authors have altered key amino acid residues in hDAO responsible for this rapid clearance, switching it into a form which has long lasting effects on histamine clearance in plasma. This recombinant protein could now be tested in clinical trials as a biopharmaceutical.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Betty Diamond as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Jeremy Turnbull (Reviewer #1); Ding Xu (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. The study lacks a key in vivo experiment to demonstrate the translational potential of the HBM mutant. It is true that the clearance of the mutant was greatly reduced, but the authors need to show that the mutant really works better than WT in vivo. This experiment should not be hard to carry out, and can be as simple as injecting animals with histamine, and then inject WT versus mutant DAO followed by measuring remaining histamine concentration in the plasma at different time points.</p><p>2. It is uncommon to mutate basic residues to serine and threonine because these polar residues can still potentially form hydrogen bonds with HS. Have the authors checked alanine mutations (most commonly used to screen HS-binding residues) or glutamine mutations (which electrostatically repels HS) of these residues. There is a good chance that these mutants might give even better reduction in HS-binding and improved clearance profile.</p><p>3. To ensure that the enzymatic activity of the HBM mutant was not affected, the authors need to perform an activity assay with dose range of DAO. The current dose (Figure 5A) at 6 nM is apparently too high to detect any potential difference in activity between WT and mutants because all substrate was fully degraded within 15 mins, and there was no time points before 15 mins.</p><p>4. Figure 5 and text – some comparison in vivo data with WT protein would be a valuable addition.</p><p>5. Figure 1B: more explanation of why some error bars are missing is needed for clarity (not just that the amounts were &gt;500nM).</p><p>6. Table 1: should state peak concentration for elution.</p><p>7. Table 2: its not clear why for the mice data it says &quot;Fold-increase WT etc..&quot; in the middle of the section in table.</p><p>8. Figure 4: difference between A and B not clear from legend.</p><p>9. Most panels (B-G) in Figure 6 are unnecessary and confusing. I can't really see what is the point of panel B and C and what all these labeled distances for. Panel D and E were shown in two different orientation and scales, which really didn't help understanding. Panel F and G are totally unnecessary.</p><p>10. Table I, it's not very meaningful, and can be misleading, to express the mutant binding to heparin Sepharose as a % binding of WT. The proper way is to list the reduction in NaCl concentration that is required for elusion.</p><p>11. The Discussion can be much more concise and the authors should limit the discussion to points directly related to the current study. For instance, the discussion about potential anti-drug antibodies was not necessary.<italic>Reviewer #1:</italic></p><p>High histamine concentrations in plasma are an issue in certain clinical settings, and anti-histamines cannot always rescue this. The human enzyme diamine oxidase (hDAO) can rapidly degrade histamine, but unfortunately is cleared from blood too rapidly after injection. In this study the authors aimed to alter key amino acid residues in hDAO responsible for this rapid clearance, with the goal of creating a form which has long lasting effects on histamine clearance in plasma. The manuscripts strengths are a coherent and convincing combination of biochemical, cellular, molecular modelling and in vivo pharmacokinetic and activity data. Weaknesses are a few minor issues with clarity of some figure legends and tables, and possible need for additional in vivo data on wild type protein. Overall the authors claims are well supported and indicate that this recombinant protein could now be tested in clinical trials as a biopharmaceutical.</p><p><italic>Reviewer #2:</italic></p><p>In this manuscript the authors aimed to find a way to improve the pharmacokinetics of human diamine oxidase (DAO), an enzyme that rapidly degrades histamine. Although DAO has a clear potential for treating diseases with excessive histamine, the clearance rate of recombinant hDAO was extremely fast (5 min), which severely hinders the effectiveness of the treatment. Previously the group has identified cell surface heparan sulfate (HS) as the main uptake receptor for hDAO, which might also play a role in the rapid clearance of hDAO in vivo. They have shown convincingly that by mutating several putative HS-binding residues of hDAO, the clearance rate of hDAO was dramatically improved to 6 hours. These mutations appeared to have no negative impact on hDAO activity, however this point will need to be more rigorously tested. This study will be a nice example showing that manipulating protein-HS interactions can have profound impact on the pharmacokinetics of therapeutically useful HS-binding proteins. In the current form however, the study lacks a key in vivo experiment to demonstrate whether the mutant truly works better than WT hDAO.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68542.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. The study lacks a key in vivo experiment to demonstrate the translational potential of the HBM mutant. It is true that the clearance of the mutant was greatly reduced, but the authors need to show that the mutant really works better than WT in vivo. This experiment should not be hard to carry out, and can be as simple as injecting animals with histamine, and then inject WT versus mutant DAO followed by measuring remaining histamine concentration in the plasma at different time points.</p></disp-quote><p>We tend not to entirely agree with this statement for several reasons. This is not a competition between wildtype DAO and heparin-binding motif mutated DAO. Wildtype DAO is not suitable for further development considering that GMP manufacturing costs several million $/€. It is possible to only move one variant to the next development stage and it will certainly not be the wildtype DAO variant. Enzymes show in most cases a clear dose response (we have shown this with DAO many times in suitable substrate and enzyme concentration ranges) and as you can see from the submitted data wildtype DAO concentrations are manifold lower within a few minutes compared to mutated variants and therefore wildtype DAO can only degrade a fraction of the histamine compared to mutated DAO. It is somewhat unethical to perform an animal experiment, where the result is clear before the experiment is done and this is also the reason, why we never did these kinds of experiments. The knowledge gain is minimal and as mentioned above patients will never be treated with wildtype DAO. Our animal experiment protocol expired a few months ago and writing a new protocol and receiving approval would take at least 6 to 9 months. This effort with minimal scientific gain is not an optimal use of anyway constrained resources. The ethics committee might also not allow such experiments, because if there is no or a minimal concentration of enzyme, histamine cannot be degraded and testing/killing animals with no clear scientific gain/rational is unethical.</p><p>Nevertheless, we totally agree that the mutated enzyme should be tested for its ability to rapidly degrade histamine in vivo or modify histamine-dependent symptoms in animal models, but not necessarily in comparison with wildtype DAO. We are currently writing an animal protocol doing such experiments. Unfortunately, clear histamine dependent pathologies in mice/rats are not really available because it seems that other mediators like PAF and serotonin play a more prominent role, e.g. in anaphylaxis. There are no animal models in chronic urticaria or mast cell activation syndrome, two other human diseases, where histamine plays an important role. It might sound easy to inject histamine into mice but the kidney removes 50% of circulating histamine in two minutes under normal kidney function and histamine sensitivity of rodents is at least 100- to 1000-fold lower and therefore high concentrations of histamine are necessary to induce symptoms. We know from many experiments using human plasma that once we have reasonable DAO concentrations present we cannot measure histamine anymore, because it is rapidly degraded.</p><p>We guess it is an editorial decision because for the reasons expressed above we have difficulties performing the proposed experiment. The other reviewer seems to concur using “possible need for additional in vivo data”.</p><disp-quote content-type="editor-comment"><p>2. It is uncommon to mutate basic residues to serine and threonine because these polar residues can still potentially form hydrogen bonds with HS. Have the authors checked alanine mutations (most commonly used to screen HS-binding residues) or glutamine mutations (which electrostatically repels HS) of these residues. There is a good chance that these mutants might give even better reduction in HS-binding and improved clearance profile.</p></disp-quote><p>One to two positively charged amino acids of the putative heparin-binding motif (F)RFKRKLPK at the amino acids 568-575 were replaced by slightly polar serine or threonine that potentially preserve the structural integrity of the protein. Threonine and serine have been used to replace arginine residues in the heparin-binding site of fibronectin, resulting in significantly reduced binding affinities, while at the same time retaining the protein’s three-dimensional structure (Busby et al., 1995; Kapila et al., 2001). The replacement with these slightly polar amino acids resulted in two mutants (R571T and R571T/K575T) that could not be successfully expressed in CHO cells. Hence, the exchange of the positively charged amino acids with non-polar alanine could potentially disrupt the local protein fold. Glutamine might behave similarly and might be also more immunogenic compared to threonine or serine due to its larger size.</p><p>We agree that the exchange with alanine would be scientifically interesting, but we believe that our study shows that the exchange of positively charged amino acids in the heparin-binding motif of DAO with serine and threonine more or less completely inhibits the interaction with heparin and heparan sulfate and cellular uptake. The α‑distribution half-life is eliminated using the arginine double mutant and therefore it is not clear that clearance could be further reduced using other mutants. The β‑elimination half-life is similar to wildtype DAO arguing against the involvement of the heparin binding motif in the β‑elimination half-life and therefore it is unlikely that clearance might be changed.</p><p>We might not have pointed this out sufficiently in the Discussion section and have therefore added the following text (lines 267-275 and 282-300):</p><p>“BLAST analysis of the RFKRKLPK motif revealed a high sequence identity of R568 and K575 in all mammalian DAO sequences analyzed. Our experimental data suggest the essential role of the conserved R568 residue in the heparin binding of DAO, which is supported by the <italic>in silico</italic> modeling comparing the interactions of wildtype and mutant DAO with the docked heparin hexasaccharide. While the single mutation of this amino acid was sufficient to achieve a comparable decrease in binding to heparin-sepharose versus the double mutants, a strong reduction of cellular uptake was only accomplished with the double mutants. Neither ITC, nor BLI detected any interaction of rhDAO-R568S/R571T with HMWH and HS…………… Incubation of various cell lines with rhDAO-R568S/R571T did not completely abrogate cellular uptake but flow cytometry and western blot analyses showed that at least 15% of the internalization cannot be attributed to HSPG interaction. This is in accordance with our previous study, where a 100-fold excess of HMWH over rhDAO-WT could not reduce the uptake below 5% and 25% in various cell lines (Gludovacz et al., 2020). In the same study we observed the presence of high affinity binding sites in HUVEC/TERT2 cells in addition to the low affinity HSPG binding sites. Similarly, cellular binding of Amyloid Protein Precursor and Fibroblast Growth Factor 2 is predominantly mediated by low affinity HSPG interactions that serve as scaffolds or co-receptors that promote and/or stabilize the formation of complexes of proteins and high-affinity receptors (Duchesne et al., 2012; Reinhard et al., 2013; Thompson et al., 1994; Xu and Esko, 2014). Since the HS-binding sites can outnumber the amount of protein-specific receptors by 100- to 1000-fold (Duchesne et al., 2012), it is not surprising that only a low proportion of binding can be attributed to the latter. These high affinity binding sites might be responsible for the β‑elimination of the heparin-binding mutants. Our data are in agreement with this hypothesis. While the clearance of more than 90% of the rhDAO-WT dose in the fast α‑elimination phase of less than five minutes is fully abrogated by the double mutation of R568 and R571, the long β‑elimination phase of about six hours is more or less unchanged. It is therefore likely that this second phase is determined by a different clearance mechanism independent of the heparin binding domain.”</p><p>Busby TF, Argraves WS, Brew SA, Pechik I, Gilliland GL, Ingham KC. 1995. Heparin Binding by Fibronectin Module III-13 Involves Six Discontinuous Basic Residues Brought Together to Form a Cationic Cradle (∗). <italic>Journal of Biological Chemistry</italic> 270:18558–18562. doi:10.1074/jbc.270.31.18558</p><p>Duchesne L, Octeau V, Bearon RN, Beckett A, Prior IA, Lounis B, Fernig DG. 2012. Transport of Fibroblast Growth Factor 2 in the Pericellular Matrix Is Controlled by the Spatial Distribution of Its Binding Sites in Heparan Sulfate. <italic>PLOS Biology</italic> 10:e1001361. doi:10.1371/journal.pbio.1001361</p><p>Gludovacz E, Schuetzenberger K, Resch M, Tillmann K, Petroczi K, Vondra S, Vakal S, Schosserer M, Virgolini N, Pollheimer J, Salminen TA, Jilma B, Borth N, Boehm T. 2020. Human diamine oxidase cellular binding and internalization in vitro and rapid clearance in vivo are not mediated by N-glycans but by heparan sulfate proteoglycan interactions. <italic>Glycobiology</italic>. doi:10.1093/glycob/cwaa090</p><p>Kapila Y, Doan D, Tafolla E, Fletterick R. 2001. Three-dimensional structural analysis of fibronectin heparin-binding domain mutations. <italic>J Cell Biochem Suppl</italic> Suppl 36:156–161. doi:10.1002/jcb.1095</p><p>Reinhard C, Borgers M, David G, Strooper BD. 2013. Soluble amyloid-β precursor protein binds its cell surface receptor in a cooperative fashion with glypican and syndecan proteoglycans. <italic>J Cell Sci</italic> 126:4856–4861. doi:10.1242/jcs.137919</p><p>Thompson LD, Pantoliano MW, Springer BA. 1994. Energetic Characterization of the Basic Fibroblast Growth Factor-Heparin Interaction: Identification of the Heparin Binding Domain. <italic>Biochemistry</italic> 33:3831–3840. doi:10.1021/bi00179a006</p><p>Xu D, Esko JD. 2014. Demystifying Heparan Sulfate–Protein Interactions. <italic>Annual Review of Biochemistry</italic> 83:129–157. doi:10.1146/annurev-biochem-060713-035314</p><disp-quote content-type="editor-comment"><p>3. To ensure that the enzymatic activity of the HBM mutant was not affected, the authors need to perform an activity assay with dose range of DAO. The current dose (Figure 5A) at 6 nM is apparently too high to detect any potential difference in activity between WT and mutants because all substrate was fully degraded within 15 mins, and there was no time points before 15 mins.</p></disp-quote><p>Again, it is not a competition between wildtype and mutant DAO because the wildtype DAO variant will never be further developed for human use. Even if the enzymatic activity of the heparin binding motif mutants were lower (which is unlikely the case = see below), one would simple use more enzyme. The necessary dosage of rhDAO enzyme administered to human patients can only be determined in appropriate Phase 2 studies, where the primary endpoint is not histamine degradation (a secondary endpoint), but symptom reduction. Therefore, it is not clear whether 6 nM or 1 µg/ml DAO is too low or too high. For rapid elimination it might be too low but for chronic treatment too high!</p><p>Nevertheless, we measured DAO activity many times, comparing wildtype with heparin-binding mutants and added one example to the supplement. Even at almost 10-fold lower DAO concentrations (we tested 6, 2 and 0.7 nM or 1, 0.33 or 0.11 µg/mL) we did not see any relevant differences in the enzymatic activity between wildtype and mutated DAO variants (see Figure 5 —figure supplement 2). Based on the published 3D structure it is also not really surprising that we did not see any activity differences, because the active center and the substrate channel are “far away” from the heparin binding motif. Nevertheless, we might have missed minor effects.</p><disp-quote content-type="editor-comment"><p>4. Figure 5 and text – some comparison in vivo data with WT protein would be a valuable addition.</p></disp-quote><p>See comments to point 1.</p><disp-quote content-type="editor-comment"><p>5. Figure 1B: more explanation of why some error bars are missing is needed for clarity (not just that the amounts were &gt;500nM).</p></disp-quote><p>The measured values where outside the standard curve and we did not remeasure the samples because the interpretation of the results would not change. We do not really understand, why the clarity would change, if the values were 550 nM or 600 nM and if error bars were shown. These values above 500 nM are compared to values &lt;5 nM, at least a 100-fold difference. The results would be under any circumstances statistically highly significant, which we did not calculate/show, because it is “obvious”. One could derive error bars from the absorption values.</p><disp-quote content-type="editor-comment"><p>6. Table 1: should state peak concentration for elution.</p></disp-quote><p>The requested information was added to the table legend.</p><disp-quote content-type="editor-comment"><p>7. Table 2: its not clear why for the mice data it says &quot;Fold-increase WT etc..&quot; in the middle of the section in table.</p></disp-quote><p>We revised the table.</p><disp-quote content-type="editor-comment"><p>8. Figure 4: difference between A and B not clear from legend.</p></disp-quote><p>We made the necessary corrections.</p><disp-quote content-type="editor-comment"><p>9. Most panels (B-G) in Figure 6 are unnecessary and confusing. I can't really see what is the point of panel B and C and what all these labeled distances for. Panel D and E were shown in two different orientation and scales, which really didn't help understanding. Panel F and G are totally unnecessary.</p></disp-quote><p>We have thoroughly revised the figure. Now, panel A shows the positively charged heparin-binding motif (HBM; blue surface) in the hDAO-WT dimer and highlights the essential residues for heparin binding; panel B demonstrates the loss of the positively charged surface in the R568S mutation; panel C illustrates that the R571T mutation reduces the positive charge and eliminates stabilizing polar interactions within the HBM in the hDAO-R571T dimer; panel D shows the predicted binding mode between hDAO-WT dimer and heparin hexasaccharide; panel E shows a dramatic loss of positive charge in hDAO-R568S/R571T dimer and stabilizing interactions with the heparin hexasaccharide.</p><p>To draw the reader’s attention to the main point of each figure, we added dashed black frames to the specific polar interactions of hDAO-WT and dashed red frames to the regions where a positive surface charge is lost in the mutants. The labels for bonds were removed, and the stick width for residues was reduced to make the pictures clearer. According to the reviewer’s suggestion, we removed panels F and G from Figure 6 and incorporated them into Figure 6 —figure supplement 1. Now, Figure 6 —figure supplement 1F and 1G respectively show specific interactions of residues 568 and 571 in hDAO-WT and hDAO-R568S/R571T mutant. From the 2D diagrams (panels C, D, F, and G), one can easily see which interactions are lost due to a specific mutation.</p><disp-quote content-type="editor-comment"><p>10. Table I, it's not very meaningful, and can be misleading, to express the mutant binding to heparin Sepharose as a % binding of WT. The proper way is to list the reduction in NaCl concentration that is required for elusion.</p></disp-quote><p>We made the requested alterations in Table 1 and Figure 6 —figure supplement 2.</p><disp-quote content-type="editor-comment"><p>11. The Discussion can be much more concise and the authors should limit the discussion to points directly related to the current study. For instance, the discussion about potential anti-drug antibodies was not necessary.</p></disp-quote><p>We revised the Discussion section.</p></body></sub-article></article>